{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:23:39Z","timestamp":1792419819431,"version":"4.5.0"},"reference-count":476,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02620-x","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:26:44Z","timestamp":1774708004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiarui","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Lobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"10","key":"2620_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1007\/s00125-020-05203-7","volume":"63","author":"MA Atkinson","year":"2020","unstructured":"Atkinson MA, Campbell-Thompson M, Kusmartseva I, Kaestner KH. Organisation of the human pancreas in health and in diabetes. Diabetologia. 2020;63(10):1966\u201373.","journal-title":"Diabetologia"},{"issue":"8","key":"2620_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/pin.12837","volume":"69","author":"Y Matsuda","year":"2019","unstructured":"Matsuda Y. Age-related morphological changes in the pancreas and their association with pancreatic carcinogenesis. Pathol Int. 2019;69(8):450\u201362.","journal-title":"Pathol Int"},{"issue":"8","key":"2620_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354.","journal-title":"Cell"},{"issue":"6","key":"2620_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/oncolo\/oyac028","volume":"27","author":"R Elias","year":"2022","unstructured":"Elias R, Cockrum P, Surinach A, Wang S, Chul Chu B, Shahrokni A. Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncologist. 2022;27(6):469\u201375.","journal-title":"Oncologist"},{"key":"2620_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2020.11.040","volume":"145","author":"S Zanini","year":"2021","unstructured":"Zanini S, Renzi S, Limongi AR, Bellavite P, Giovinazzo F, Bermano G. A review of lifestyle and environment risk factors for pancreatic cancer. Eur J Cancer. 2021;145:53\u201370.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2620_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01750-4","volume":"17","author":"J Yang","year":"2025","unstructured":"Yang J, Wen C, Guo H, Chai Y, Sun G, Cheng H. Targeting early diagnosis and treatment of pancreatic cancer among the diabetic population: a comprehensive review of biomarker screening strategies. Diabetol Metab Syndr. 2025;17(1):176.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"2620_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer Genome Atlas Research N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185\u2013203. e13.","journal-title":"Cancer Cell"},{"issue":"1","key":"2620_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41420-024-01890-y","volume":"10","author":"S Zhang","year":"2024","unstructured":"Zhang S, Yun D, Yang H, Eckstein M, Elbait GD, Zhou Y, et al. Roflumilast inhibits tumor growth and migration in STK11\/LKB1 deficient pancreatic cancer. Cell Death Discov. 2024;10(1):124.","journal-title":"Cell Death Discov"},{"issue":"7","key":"2620_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/gim.2014.153","volume":"17","author":"DB Zhen","year":"2015","unstructured":"Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17(7):569\u201377.","journal-title":"Genet Med"},{"issue":"3","key":"2620_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"2620_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cancergen.2016.03.003","volume":"209","author":"M Borecka","year":"2016","unstructured":"Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, et al. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genet. 2016;209(5):199\u2013204.","journal-title":"Cancer Genet"},{"key":"2620_CR12","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2620_CR13","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-94","volume":"13","author":"ECH Lai","year":"2024","unstructured":"Lai ECH, Ung AKY. Update on management of pancreatic cancer: a literature review. Chin Clin Oncol. 2024;13(3):41.","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"2620_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","volume":"16","author":"O Strobel","year":"2019","unstructured":"Strobel O, Neoptolemos J, Jager D, Buchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11\u201326.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2620_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12029-025-01287-9","volume":"56","author":"AM Khan","year":"2025","unstructured":"Khan AM, Muddu VK, Bonda NA, Siripurapu I, Ahmed R, Takreem S, et al. FOLFIRINOX vs. Gemcitabine Nab-Paclitaxel in Pancreatic Cancer: A Real-World Single-Center Analysis of Efficacy and Safety. J Gastrointest Cancer. 2025;56(1):173.","journal-title":"J Gastrointest Cancer"},{"issue":"9","key":"2620_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263\u201370.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2620_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","volume":"10","author":"M Cecchini","year":"2024","unstructured":"Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, et al. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2024;10(8):1027\u201335.","journal-title":"JAMA Oncol"},{"key":"2620_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1488645","volume":"15","author":"Z Xiang","year":"2024","unstructured":"Xiang Z, Ma L, Li Z, Fu Y, Pan Y. Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China. Front Pharmacol. 2024;15:1488645.","journal-title":"Front Pharmacol"},{"key":"2620_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041129","author":"U Hayat","year":"2025","unstructured":"Hayat U, Croce PS, Saadeh A, Desai K, Appiah J, Khan S, et al. Current and emerging treatment options for pancreatic cancer: a comprehensive review. J Clin Med. 2025;14(4). https:\/\/doi.org\/10.3390\/jcm14041129.","journal-title":"J Clin Med"},{"issue":"17","key":"2620_CR20","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844\u201353.","journal-title":"JAMA"},{"issue":"3","key":"2620_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022;3(3):272\u201386.","journal-title":"Nat Cancer"},{"issue":"2","key":"2620_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173\u201381.","journal-title":"World J Gastrointest Oncol"},{"issue":"8","key":"2620_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2620_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"6349","key":"2620_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"key":"2620_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187024","author":"K Sun","year":"2025","unstructured":"Sun K, Zhang X, Shi J, Huang J, Wang S, Li X, et al. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. J Clin Invest. 2025;135(7). https:\/\/doi.org\/10.1172\/JCI187024.","journal-title":"J Clin Invest"},{"key":"2620_CR27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190354","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217(12). https:\/\/doi.org\/10.1084\/jem.20190354.","journal-title":"J Exp Med"},{"key":"2620_CR28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240766","author":"D Deng","year":"2024","unstructured":"Deng D, Begum H, Liu T, Zhang J, Zhang Q, Chu TY, et al. NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer. J Exp Med. 2024;221(11). https:\/\/doi.org\/10.1084\/jem.20240766.","journal-title":"J Exp Med"},{"key":"2620_CR29","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.drup.2024.101079","volume":"74","author":"W Huang","year":"2024","unstructured":"Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, et al. TRIM29 facilitates gemcitabine resistance via MEK\/ERK pathway and is modulated by circRPS29\/miR-770-5p axis in PDAC. Drug Resist Updat. 2024;74:101079.","journal-title":"Drug Resist Updat"},{"issue":"11","key":"2620_CR30","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal A, Styers HC, Rub J, Li Z, Torborg SR, Kim JY, et al. A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024;14(11):2122\u201334.","journal-title":"Cancer Discov"},{"issue":"6","key":"2620_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molmed.2024.03.008","volume":"30","author":"MC De Santis","year":"2024","unstructured":"De Santis MC, Bockorny B, Hirsch E, Cappello P, Martini M. Exploiting pancreatic cancer metabolism: challenges and opportunities. Trends Mol Med. 2024;30(6):592\u2013604.","journal-title":"Trends Mol Med"},{"issue":"25","key":"2620_CR32","doi-asserted-by":"publisher","first-page":"eadj8650","DOI":"10.1126\/sciadv.adj8650","volume":"10","author":"H Sun","year":"2024","unstructured":"Sun H, Li H, Guan Y, Yuan Y, Xu C, Fu D, et al. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Sci Adv. 2024;10(25):eadj8650.","journal-title":"Sci Adv"},{"issue":"4","key":"2620_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189373","volume":"1880","author":"F Gao","year":"2025","unstructured":"Gao F, Sun K, Wang S, Zhang X, Bai X. Lactate metabolism reprogramming in PDAC: potential for tumor therapy. Biochim Biophys Acta Rev Cancer. 2025;1880(4):189373.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"2620_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00018-019-03278-z","volume":"77","author":"J Yang","year":"2020","unstructured":"Yang J, Ren B, Yang G, Wang H, Chen G, You L, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2020;77(2):305\u201321.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2620_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-025-02141-x","volume":"10","author":"H Liu","year":"2025","unstructured":"Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduct Target Ther. 2025;10(1):69.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2620_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.218","volume":"4","author":"S Nong","year":"2023","unstructured":"Nong S, Han X, Xiang Y, Qian Y, Wei Y, Zhang T, et al. Metabolic reprogramming in cancer: mechanisms and therapeutics. MedComm. 2023;4(2):e218.","journal-title":"MedComm"},{"issue":"4","key":"2620_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657\u201369.","journal-title":"Cell"},{"issue":"1","key":"2620_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23(1):203.","journal-title":"Mol Cancer"},{"issue":"1\u20132","key":"2620_CR39","first-page":"36","volume":"39","author":"H Ying","year":"2025","unstructured":"Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025;39(1\u20132):36\u201363.","journal-title":"Genes Dev"},{"issue":"2","key":"2620_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","volume":"39","author":"KL Bryant","year":"2014","unstructured":"Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39(2):91\u2013100.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2620_CR41","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1038\/s41467-018-07472-8","volume":"9","author":"N Santana-Codina","year":"2018","unstructured":"Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun. 2018;9(1):4945.","journal-title":"Nat Commun"},{"issue":"1","key":"2620_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","volume":"126","author":"K Bensaad","year":"2006","unstructured":"Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107\u201320.","journal-title":"Cell"},{"issue":"16","key":"2620_CR43","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1158\/0008-5472.CAN-15-0108","volume":"75","author":"NV Rajeshkumar","year":"2015","unstructured":"Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, et al. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer Res. 2015;75(16):3355\u201364.","journal-title":"Cancer Res"},{"issue":"5780","key":"2620_CR44","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1126863","volume":"312","author":"S Matoba","year":"2006","unstructured":"Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650\u20133.","journal-title":"Science"},{"issue":"4","key":"2620_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molcel.2017.07.014","volume":"67","author":"A Nagarajan","year":"2017","unstructured":"Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol Cell. 2017;67(4):685-701 e6.","journal-title":"Mol Cell"},{"issue":"5","key":"2620_CR46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/gutjnl-2018-317163","volume":"69","author":"C Liang","year":"2020","unstructured":"Liang C, Shi S, Qin Y, Meng Q, Hua J, Hu Q, et al. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut. 2020;69(5):888\u2013900.","journal-title":"Gut"},{"issue":"3","key":"2620_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656\u201370.","journal-title":"Cell"},{"issue":"12","key":"2620_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tcb.2025.04.007","volume":"35","author":"R Thakur","year":"2025","unstructured":"Thakur R, Mullen NJ, Mehla K, Singh PK. Tumor-stromal metabolic crosstalk in pancreatic cancer. Trends Cell Biol. 2025;35(12):1068\u201383.","journal-title":"Trends Cell Biol"},{"issue":"12","key":"2620_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115064","volume":"43","author":"Y Mao","year":"2024","unstructured":"Mao Y, Xia Z, Xia W, Jiang P. Metabolic reprogramming, sensing, and cancer therapy. Cell Rep. 2024;43(12):115064.","journal-title":"Cell Rep"},{"issue":"4","key":"2620_CR50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2478\/jtim-2022-0022","volume":"11","author":"X Shen","year":"2023","unstructured":"Shen X, Niu N, Xue J. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. J Transl Int Med. 2023;11(4):322\u20139.","journal-title":"J Transl Int Med"},{"issue":"1","key":"2620_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cmet.2020.10.017","volume":"33","author":"XG Zhu","year":"2021","unstructured":"Zhu XG, Chudnovskiy A, Baudrier L, Prizer B, Liu Y, Ostendorf BN, et al. Functional Genomics In Vivo Reveal Metabolic Dependencies of Pancreatic Cancer Cells. Cell Metab. 2021;33(1):211\u201321. e6.","journal-title":"Cell Metab"},{"issue":"9","key":"2620_CR52","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1158\/2159-8290.CD-22-0044","volume":"12","author":"M Ravichandran","year":"2022","unstructured":"Ravichandran M, Hu J, Cai C, Ward NP, Venida A, Foakes C, et al. Coordinated transcriptional and catabolic programs support iron-dependent adaptation to RAS-MAPK pathway inhibition in pancreatic cancer. Cancer Discov. 2022;12(9):2198\u2013219.","journal-title":"Cancer Discov"},{"key":"2620_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102089","volume":"92","author":"N Ghiglione","year":"2025","unstructured":"Ghiglione N, Abbo D, Bushunova A, Costamagna A, Porporato PE, Martini M. Metabolic plasticity in pancreatic cancer: the mitochondrial connection. Mol Metab. 2025;92:102089.","journal-title":"Mol Metab"},{"issue":"1","key":"2620_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.","journal-title":"Mol Cancer"},{"issue":"3","key":"2620_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2620_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-022-01206-5","volume":"7","author":"X Li","year":"2022","unstructured":"Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, et al. Correction: Lactate metabolism in human health and disease. Signal Transduct Target Ther. 2022;7(1):372.","journal-title":"Signal Transduct Target Ther"},{"key":"2620_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564603","volume":"16","author":"J Shi","year":"2025","unstructured":"Shi J, Cui X, Wang J, Liu G, Meng J, Zhang Y. Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy. Front Immunol. 2025;16:1564603.","journal-title":"Front Immunol"},{"issue":"21","key":"2620_CR58","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-24-2860","volume":"84","author":"ES Carpenter","year":"2024","unstructured":"Carpenter ES, Vendramini-Costa DB, Hasselluhn MC, Maitra A, Olive KP, Cukierman E, et al. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Cancer Res. 2024;84(21):3505\u20138.","journal-title":"Cancer Res"},{"key":"2620_CR59","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5357","author":"L Liang","year":"2022","unstructured":"Liang L, Li W, Li X, Jin X, Liao Q, Li Y, et al. \u201cReverse warburg effect\u201d of cancer\u2011associated fibroblasts (Review). Int J Oncol. 2022;60(6). https:\/\/doi.org\/10.3892\/ijo.2022.5357.","journal-title":"Int J Oncol"},{"key":"2620_CR60","doi-asserted-by":"publisher","first-page":"1152312","DOI":"10.3389\/fimmu.2023.1152312","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Zhou J, Wang X, Li C, Ma Z, Wan Q, et al. Pancreatic cancer and fibrosis: Targeting metabolic reprogramming and crosstalk of cancer-associated fibroblasts in the tumor microenvironment. Front Immunol. 2023;14:1152312.","journal-title":"Front Immunol"},{"issue":"1","key":"2620_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41392-025-02129-7","volume":"10","author":"R Nussinov","year":"2025","unstructured":"Nussinov R, Yavuz BR, Jang H. Molecular principles underlying aggressive cancers. Signal Transduct Target Ther. 2025;10(1):42.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2620_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, Deng L, Ouyang Q, Zhang XH, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):57.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2620_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.canlet.2016.07.022","volume":"381","author":"S Midha","year":"2016","unstructured":"Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett. 2016;381(1):269\u201377.","journal-title":"Cancer Lett"},{"key":"2620_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2018.09.007","volume":"104","author":"A Lugo","year":"2018","unstructured":"Lugo A, Peveri G, Bosetti C, Bagnardi V, Crippa A, Orsini N, et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis. Eur J Cancer. 2018;104:117\u201326.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2620_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12866-024-03688-5","volume":"24","author":"X Liang","year":"2024","unstructured":"Liang X, Zhu Y, Bu Y, Dong M, Zhang G, Chen C, et al. Microbiome and metabolome analysis in smoking and non-smoking pancreatic ductal adenocarcinoma patients. BMC Microbiol. 2024;24(1):541.","journal-title":"BMC Microbiol"},{"issue":"5","key":"2620_CR66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/MPA.0000000000001550","volume":"49","author":"S Weissman","year":"2020","unstructured":"Weissman S, Takakura K, Eibl G, Pandol SJ, Saruta M. The diverse involvement of cigarette smoking in pancreatic cancer development and prognosis. Pancreas. 2020;49(5):612\u201320.","journal-title":"Pancreas"},{"key":"2620_CR67","doi-asserted-by":"publisher","first-page":"112312","DOI":"10.1016\/j.biopha.2021.112312","volume":"144","author":"V Gunda","year":"2021","unstructured":"Gunda V, Chhonker YS, Natesh NS, Raut P, Muniyan S, Wyatt TA, et al. Nuclear factor kappa-B contributes to cigarette smoke tolerance in pancreatic ductal adenocarcinoma through cysteine metabolism. Biomed Pharmacother. 2021;144:112312.","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"2620_CR68","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/onc.2014.154","volume":"34","author":"S Kumar","year":"2015","unstructured":"Kumar S, Torres MP, Kaur S, Rachagani S, Joshi S, Johansson SL, et al. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Oncogene. 2015;34(16):2052\u201360.","journal-title":"Oncogene"},{"issue":"5","key":"2620_CR69","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bpg.2017.09.001","volume":"31","author":"M Korc","year":"2017","unstructured":"Korc M, Jeon CY, Edderkaoui M, Pandol SJ, Petrov MS, Consortium for the Study of Chronic, Pancreatitis D, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31(5):529\u201336.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"2620_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-022-02240-z","volume":"22","author":"D Ali","year":"2022","unstructured":"Ali D, AlAhmari F, Mikami T, Baskaradoss JK. Increased expression of advanced glycation endproducts in the gingival crevicular fluid compromises periodontal status in cigarette-smokers and waterpipe users. BMC Oral Health. 2022;22(1):206.","journal-title":"BMC Oral Health"},{"key":"2620_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2023.135735","volume":"415","author":"Z Tian","year":"2023","unstructured":"Tian Z, Chen S, Shi Y, Wang P, Wu Y, Li G. Dietary advanced glycation end products (dAGEs): an insight between modern diet and health. Food Chem. 2023;415:135735.","journal-title":"Food Chem"},{"key":"2620_CR72","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqz006","author":"HH Ruiz","year":"2020","unstructured":"Ruiz HH, Ramasamy R, Schmidt AM. Advanced glycation end products: building on the concept of the \u201ccommon soil\u201d in metabolic disease. Endocrinology. 2020;161(1). https:\/\/doi.org\/10.1210\/endocr\/bqz006.","journal-title":"Endocrinology"},{"issue":"7","key":"2620_CR73","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1053\/j.gastro.2019.03.050","volume":"156","author":"A Saluja","year":"2019","unstructured":"Saluja A, Maitra A. Pancreatitis and pancreatic cancer. Gastroenterology. 2019;156(7):1937\u201340.","journal-title":"Gastroenterology"},{"issue":"8","key":"2620_CR74","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2174\/1871530320666200423095700","volume":"20","author":"HK Kandikattu","year":"2020","unstructured":"Kandikattu HK, Venkateshaiah SU, Mishra A. Chronic pancreatitis and the development of pancreatic cancer. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1182\u2013210.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"2620_CR75","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","volume":"7","author":"Z Luo","year":"2022","unstructured":"Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li G, et al. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct Target Ther. 2022;7(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2620_CR76","doi-asserted-by":"publisher","first-page":"e1004590","DOI":"10.1371\/journal.pmed.1004590","volume":"22","author":"S Naudin","year":"2025","unstructured":"Naudin S, Wang M, Dimou N, Ebrahimi E, Genkinger J, Adami HO, et al. Alcohol intake and pancreatic cancer risk: an analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLoS Med. 2025;22(5):e1004590.","journal-title":"PLoS Med"},{"issue":"1","key":"2620_CR77","doi-asserted-by":"publisher","first-page":"9572","DOI":"10.1038\/s41598-017-08794-1","volume":"7","author":"S Zhang","year":"2017","unstructured":"Zhang S, Wang C, Huang H, Jiang Q, Zhao D, Tian Y, et al. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. Sci Rep. 2017;7(1):9572.","journal-title":"Sci Rep"},{"issue":"2","key":"2620_CR78","doi-asserted-by":"publisher","first-page":"173","DOI":"10.35946\/arcr.v38.2.03","volume":"38","author":"VW Setiawan","year":"2017","unstructured":"Setiawan VW, Monroe K, Lugea A, Yadav D, Pandol S. Uniting epidemiology and experimental disease models for alcohol-related pancreatic disease. Alcohol Res. 2017;38(2):173\u201382.","journal-title":"Alcohol Res"},{"key":"2620_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134318","author":"N Michalak","year":"2023","unstructured":"Michalak N, Malecka-Wojciesko E. Modifiable pancreatic ductal adenocarcinoma (PDAC) risk factors. J Clin Med. 2023;12(13). https:\/\/doi.org\/10.3390\/jcm12134318.","journal-title":"J Clin Med"},{"issue":"1","key":"2620_CR80","first-page":"48","volume":"30","author":"A Vonlaufen","year":"2007","unstructured":"Vonlaufen A, Wilson JS, Pirola RC, Apte MV. Role of alcohol metabolism in chronic pancreatitis. Alcohol Res Health. 2007;30(1):48\u201354.","journal-title":"Alcohol Res Health"},{"key":"2620_CR81","doi-asserted-by":"publisher","unstructured":"Bakleh MZ, Al Haj Zen A. The Distinct Role of HIF-1alpha and HIF-2alpha in Hypoxia and Angiogenesis. Cells. 2025;14(9). https:\/\/doi.org\/10.3390\/cells14090673.","DOI":"10.3390\/cells14090673"},{"key":"2620_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/nu15204465","author":"P Gualtieri","year":"2023","unstructured":"Gualtieri P, Cianci R, Frank G, Pizzocaro E, De Santis GL, Giannattasio S, et al. Pancreatic ductal adenocarcinoma and nutrition: exploring the role of diet and gut health. Nutrients. 2023;15(20). https:\/\/doi.org\/10.3390\/nu15204465.","journal-title":"Nutrients"},{"key":"2620_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1249407","volume":"10","author":"Y Sun","year":"2023","unstructured":"Sun Y, He X, Sun Y. Red and processed meat and pancreatic cancer risk: a meta-analysis. Front Nutr. 2023;10:1249407.","journal-title":"Front Nutr"},{"key":"2620_CR84","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.clnesp.2025.03.021","volume":"67","author":"B Ghosn","year":"2025","unstructured":"Ghosn B, Baniasadi MM, Jalalzadeh M, Esmaillzadeh A. Total, unprocessed, and processed red meat intake in relation to the risk of pancreatic cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. Clin Nutr ESPEN. 2025;67:265\u201375.","journal-title":"Clin Nutr ESPEN"},{"issue":"3","key":"2620_CR85","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/bjc.2011.585","volume":"106","author":"SC Larsson","year":"2012","unstructured":"Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer. 2012;106(3):603\u20137.","journal-title":"Br J Cancer"},{"issue":"5","key":"2620_CR86","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.xcrm.2025.102091","volume":"6","author":"J Wellens","year":"2025","unstructured":"Wellens J, Vissers E, Dumoulin A, Hoekx S, Vanderstappen J, Verbeke J, et al. Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects. Cell Rep Med. 2025;6(5):102091.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2620_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cmet.2024.09.012","volume":"37","author":"K Sakamoto","year":"2025","unstructured":"Sakamoto K, Butera MA, Zhou C, Maurizi G, Chen B, Ling L, et al. Overnutrition causes insulin resistance and metabolic disorder through increased sympathetic nervous system activity. Cell Metab. 2025;37(1):121-37 e6.","journal-title":"Cell Metab"},{"issue":"1","key":"2620_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01837-y","volume":"17","author":"B Dutta","year":"2025","unstructured":"Dutta B, Tripathy A, Archana PR, Kamath SU. Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome. Diabetol Metab Syndr. 2025;17(1):292.","journal-title":"Diabetol Metab Syndr"},{"key":"2620_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13050675","author":"D Lathigara","year":"2023","unstructured":"Lathigara D, Kaushal D, Wilson RB. Molecular mechanisms of Western diet-induced obesity and obesity-related carcinogenesis-a narrative review. Metabolites. 2023;13(5). https:\/\/doi.org\/10.3390\/metabo13050675.","journal-title":"Metabolites"},{"issue":"1","key":"2620_CR90","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41392-023-01376-w","volume":"8","author":"R Ruze","year":"2023","unstructured":"Ruze R, Song J, Yin X, Chen Y, Xu R, Wang C, et al. Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. Signal Transduct Target Ther. 2023;8(1):139.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2620_CR91","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.gastro.2013.08.018","volume":"145","author":"B Philip","year":"2013","unstructured":"Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, Gomez SB, et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013;145(6):1449\u201358.","journal-title":"Gastroenterology"},{"key":"2620_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071849","author":"D Brocco","year":"2020","unstructured":"Brocco D, Florio R, De Lellis L, Veschi S, Grassadonia A, Tinari N, et al. The role of dysfunctional adipose tissue in pancreatic cancer: a molecular perspective. Cancers (Basel). 2020;12(7). https:\/\/doi.org\/10.3390\/cancers12071849.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2620_CR93","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.apsb.2025.04.029","volume":"15","author":"A Rakib","year":"2025","unstructured":"Rakib A, Mamun MAA, Mandal M, Sinha P, Singh UP. Obesity-cancer axis crosstalk: molecular insights and therapeutic approaches. Acta Pharm Sin B. 2025;15(6):2930\u201344.","journal-title":"Acta Pharm Sin B"},{"key":"2620_CR94","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2049-3002-2-18","volume":"2","author":"SK Shukla","year":"2014","unstructured":"Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18.","journal-title":"Cancer Metab"},{"key":"2620_CR95","first-page":"21","volume":"18","author":"D Nucci","year":"2021","unstructured":"Nucci D, Santangelo OE, Provenzano S, Fatigoni C, Nardi M, Ferrara P, et al. Dietary Fiber Intake and Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2021;18:21.","journal-title":"Int J Environ Res Public Health"},{"key":"2620_CR96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1743-7075-5-17","volume":"5","author":"AM Gonzales","year":"2008","unstructured":"Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab Lond. 2008;5:17.","journal-title":"Nutr Metab Lond"},{"issue":"4","key":"2620_CR97","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jand.2017.07.005","volume":"118","author":"G Eibl","year":"2018","unstructured":"Eibl G, Cruz-Monserrate Z, Korc M, Petrov MS, Goodarzi MO, Fisher WE, et al. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet. 2018;118(4):555\u201367.","journal-title":"J Acad Nutr Diet"},{"issue":"3","key":"2620_CR98","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.pcd.2018.11.015","volume":"13","author":"JJ Zhang","year":"2019","unstructured":"Zhang JJ, Jia JP, Shao Q, Wang YK. Diabetes mellitus and risk of pancreatic cancer in China: a meta-analysis based on 26 case-control studies. Prim Care Diabetes. 2019;13(3):276\u201382.","journal-title":"Prim Care Diabetes"},{"key":"2620_CR99","doi-asserted-by":"publisher","first-page":"17102","DOI":"10.1038\/srep17102","volume":"5","author":"Y Mao","year":"2015","unstructured":"Mao Y, Tao M, Jia X, Xu H, Chen K, Tang H, et al. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Sci Rep. 2015;5:17102.","journal-title":"Sci Rep"},{"issue":"2","key":"2620_CR100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41575-020-00410-4","volume":"18","author":"T Jain","year":"2021","unstructured":"Jain T, Dudeja V. The war against pancreatic cancer in 2020 - advances on all fronts. Nat Rev Gastroenterol Hepatol. 2021;18(2):99\u2013100.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2620_CR101","first-page":"100596","volume":"30","author":"B Shen","year":"2023","unstructured":"Shen B, Li Y, Sheng CS, Liu L, Hou T, Xia N, et al. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian randomization study. Lancet Reg Health West Pac. 2023;30:100596.","journal-title":"Lancet Reg Health West Pac"},{"key":"2620_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071733","author":"Z Lin","year":"2025","unstructured":"Lin Z, Adeniran EA, Cai Y, Qureshi TA, Li D, Gong J, et al. Early detection of pancreatic cancer: current advances and future opportunities. Biomedicines. 2025;13(7). https:\/\/doi.org\/10.3390\/biomedicines13071733.","journal-title":"Biomedicines"},{"issue":"10","key":"2620_CR103","doi-asserted-by":"publisher","first-page":"e202948","DOI":"10.1001\/jamaoncol.2020.2948","volume":"6","author":"C Yuan","year":"2020","unstructured":"Yuan C, Babic A, Khalaf N, Nowak JA, Brais LK, Rubinson DA, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 2020;6(10):e202948.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2620_CR104","doi-asserted-by":"publisher","first-page":"e0311911","DOI":"10.1371\/journal.pone.0311911","volume":"19","author":"X Huang","year":"2024","unstructured":"Huang X, Li H, Zhao L, Xu L, Long H. Prediabetes increases the risk of pancreatic cancer: A meta-analysis of longitudinal observational studies. PLoS One. 2024;19(10):e0311911.","journal-title":"PLoS One"},{"issue":"1","key":"2620_CR105","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12889-025-21404-4","volume":"25","author":"S Hu","year":"2025","unstructured":"Hu S, Ji W, Zhang Y, Zhu W, Sun H, Sun Y. Risk factors for progression to type 2 diabetes in prediabetes: a systematic review and meta-analysis. BMC Public Health. 2025;25(1):1220.","journal-title":"BMC Public Health"},{"key":"2620_CR106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcancer.2023.11.002","volume":"97","author":"M Srilatha","year":"2023","unstructured":"Srilatha M, Malla R, Adem MP, Foote JB, Nagaraju GP. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges. Semin Cancer Biol. 2023;97:12\u201320.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2620_CR107","first-page":"945","volume":"21","author":"Y Xu","year":"2020","unstructured":"Xu Y, Tan M, Tian X, Zhang J, Zhang J, Chen J, et al. Leptin receptor mediates the proliferation and glucose metabolism of pancreatic cancer cells via AKT pathway activation. Mol Med Rep. 2020;21(2):945\u201352.","journal-title":"Mol Med Rep"},{"key":"2620_CR108","doi-asserted-by":"publisher","first-page":"217162","DOI":"10.1016\/j.canlet.2024.217162","volume":"601","author":"R Ruze","year":"2024","unstructured":"Ruze R, Chen Y, Song J, Xu R, Yin X, Xu Q, et al. Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. Cancer Lett. 2024;601:217162.","journal-title":"Cancer Lett"},{"issue":"1","key":"2620_CR109","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"HF Yan","year":"2021","unstructured":"Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6(1):49.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2620_CR110","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cgh.2015.09.036","volume":"14","author":"K Majumder","year":"2016","unstructured":"Majumder K, Gupta A, Arora N, Singh PP, Singh S. Premorbid Obesity and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(3):355\u201368. e; quiz e32.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"2620_CR111","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/1940-6207.CAPR-13-0065","volume":"6","author":"DW Dawson","year":"2013","unstructured":"Dawson DW, Hertzer K, Moro A, Donald G, Chang HH, Go VL, et al. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila). 2013;6(10):1064\u201373.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"2620_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02499-y","volume":"11","author":"E Rozengurt","year":"2026","unstructured":"Rozengurt E, Eibl G. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. Signal Transduct Target Ther. 2026;11(1):6.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2620_CR113","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-017-0701-0","volume":"16","author":"K Chen","year":"2017","unstructured":"Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer. 2017;16(1):131.","journal-title":"Mol Cancer"},{"issue":"7","key":"2620_CR114","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","volume":"40","author":"E Kurz","year":"2022","unstructured":"Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, Miller G, et al. Exercise-induced engagement of the IL-15\/IL-15Ralpha axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell. 2022;40(7):720\u201337. e5.","journal-title":"Cancer Cell"},{"issue":"4","key":"2620_CR115","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.cell.2020.03.062","volume":"181","author":"KM Chung","year":"2020","unstructured":"Chung KM, Singh J, Lawres L, Dorans KJ, Garcia C, Burkhardt DB, et al. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell. 2020;181(4):832\u201347. e18.","journal-title":"Cell"},{"issue":"4","key":"2620_CR116","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/cdd.2009.149","volume":"17","author":"R Kang","year":"2010","unstructured":"Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010;17(4):666\u201376.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2620_CR117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2620_CR118","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","volume":"8","author":"S Pushalkar","year":"2018","unstructured":"Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018;8(4):403\u201316.","journal-title":"Cancer Discov"},{"issue":"1","key":"2620_CR119","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s42003-021-02557-5","volume":"4","author":"W Guo","year":"2021","unstructured":"Guo W, Zhang Y, Guo S, Mei Z, Liao H, Dong H, et al. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol. 2021;4(1):1019.","journal-title":"Commun Biol"},{"issue":"756","key":"2620_CR120","doi-asserted-by":"publisher","first-page":"eabn4948","DOI":"10.1126\/scisignal.abn4948","volume":"15","author":"B Udayasuryan","year":"2022","unstructured":"Udayasuryan B, Ahmad RN, Nguyen TTD, Umana A, Monet Roberts L, Sobol P, et al. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal. 2022;15(756):eabn4948.","journal-title":"Sci Signal"},{"issue":"4","key":"2620_CR121","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","volume":"178","author":"E Riquelme","year":"2019","unstructured":"Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019;178(4):795\u2013806. e12.","journal-title":"Cell"},{"key":"2620_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082331","author":"J Gnanasekaran","year":"2020","unstructured":"Gnanasekaran J, Binder Gallimidi A, Saba E, Pandi K, Eli Berchoer L, Hermano E, et al. Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers (Basel). 2020;12(8). https:\/\/doi.org\/10.3390\/cancers12082331.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2620_CR123","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/gutjnl-2023-330941","volume":"73","author":"E Saba","year":"2024","unstructured":"Saba E, Farhat M, Daoud A, Khashan A, Forkush E, Menahem NH, et al. Oral bacteria accelerate pancreatic cancer development in mice. Gut. 2024;73(5):770\u201386.","journal-title":"Gut"},{"issue":"1","key":"2620_CR124","doi-asserted-by":"publisher","first-page":"2073785","DOI":"10.1080\/19490976.2022.2073785","volume":"14","author":"Q Tan","year":"2022","unstructured":"Tan Q, Ma X, Yang B, Liu Y, Xie Y, Wang X, et al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. 2022;14(1):2073785.","journal-title":"Gut Microbes"},{"key":"2620_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/biom15071018","author":"G Xu","year":"2025","unstructured":"Xu G, Jiang Y, Sun C, Brandt BW, Nazmi K, Morelli L, et al. Role of oral bacteria in mediating gemcitabine resistance in pancreatic cancer. Biomolecules. 2025;15(7). https:\/\/doi.org\/10.3390\/biom15071018.","journal-title":"Biomolecules"},{"key":"2620_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184479","author":"K Miyabayashi","year":"2022","unstructured":"Miyabayashi K, Ijichi H, Fujishiro M. The role of the microbiome in pancreatic cancer. Cancers (Basel). 2022;14(18). https:\/\/doi.org\/10.3390\/cancers14184479.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2620_CR127","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/gutjnl-2011-300784","volume":"61","author":"JJ Farrell","year":"2012","unstructured":"Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61(4):582\u20138.","journal-title":"Gut"},{"issue":"48","key":"2620_CR128","doi-asserted-by":"publisher","first-page":"7679","DOI":"10.3748\/wjg.v26.i48.7679","volume":"26","author":"AL Wei","year":"2020","unstructured":"Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol. 2020;26(48):7679\u201392.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2620_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2320280","volume":"16","author":"MS Cruz","year":"2024","unstructured":"Cruz MS, Tintelnot J, Gagliani N. Roles of microbiota in pancreatic cancer development and treatment. Gut Microbes. 2024;16(1):2320280.","journal-title":"Gut Microbes"},{"issue":"Pt 3","key":"2620_CR130","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.semcancer.2021.05.027","volume":"86","author":"G Pandya","year":"2022","unstructured":"Pandya G, Kirtonia A, Singh A, Goel A, Mohan CD, Rangappa KS, et al. A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma. Semin Cancer Biol. 2022;86(Pt 3):682\u201392.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2620_CR131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s10020-025-01166-w","volume":"31","author":"X Guo","year":"2025","unstructured":"Guo X, Shao Y. Role of the oral-gut microbiota axis in pancreatic cancer: a new perspective on tumor pathophysiology, diagnosis, and treatment. Mol Med. 2025;31(1):103.","journal-title":"Mol Med"},{"key":"2620_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120565","author":"S Ciernikova","year":"2020","unstructured":"Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The emerging role of microbiota and microbiome in pancreatic ductal adenocarcinoma. Biomedicines. 2020;8(12). https:\/\/doi.org\/10.3390\/biomedicines8120565.","journal-title":"Biomedicines"},{"issue":"1","key":"2620_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 2020;5(1):108.","journal-title":"Signal Transduct Target Ther"},{"key":"2620_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10030083","author":"H Armstrong","year":"2018","unstructured":"Armstrong H, Bording-Jorgensen M, Dijk S, Wine E. The complex interplay between chronic inflammation, the microbiome, and cancer: understanding disease progression and what we can do to prevent it. Cancers (Basel). 2018;10(3). https:\/\/doi.org\/10.3390\/cancers10030083.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2620_CR135","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/1040841X.2022.2080526","volume":"49","author":"Y Fang","year":"2023","unstructured":"Fang Y, Yang G, Yang J, Ren J, You L, Zhao Y. Human microbiota colonization and pancreatic ductal carcinoma. Crit Rev Microbiol. 2023;49(4):455\u201368.","journal-title":"Crit Rev Microbiol"},{"issue":"1","key":"2620_CR136","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/gutjnl-2016-312580","volume":"67","author":"X Fan","year":"2018","unstructured":"Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120\u20137.","journal-title":"Gut"},{"key":"2620_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312743","author":"A Orlacchio","year":"2021","unstructured":"Orlacchio A, Mazzone P. The role of Toll-like receptors (TLRs) mediated inflammation in pancreatic cancer pathophysiology. Int J Mol Sci. 2021;22(23). https:\/\/doi.org\/10.3390\/ijms222312743.","journal-title":"Int J Mol Sci"},{"issue":"6356","key":"2620_CR138","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156\u201360.","journal-title":"Science"},{"key":"2620_CR139","doi-asserted-by":"publisher","first-page":"113163","DOI":"10.1016\/j.biopha.2022.113163","volume":"151","author":"C Panebianco","year":"2022","unstructured":"Panebianco C, Villani A, Pisati F, Orsenigo F, Ulaszewska M, Latiano TP, et al. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Biomed Pharmacother. 2022;151:113163.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2620_CR140","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell. 2008;134(5):703\u20137.","journal-title":"Cell"},{"issue":"12","key":"2620_CR141","doi-asserted-by":"publisher","first-page":"113434","DOI":"10.1016\/j.celrep.2023.113434","volume":"42","author":"Y Ohara","year":"2023","unstructured":"Ohara Y, Tang W, Liu H, Yang S, Dorsey TH, Cawley H, et al. SERPINB3-MYC axis induces the basal-like\/squamous subtype and enhances disease progression in pancreatic cancer. Cell Rep. 2023;42(12):113434.","journal-title":"Cell Rep"},{"issue":"2","key":"2620_CR142","first-page":"861","volume":"12","author":"X Chang","year":"2022","unstructured":"Chang X, Liu X, Wang H, Yang X, Gu Y. Glycolysis in the progression of pancreatic cancer. Am J Cancer Res. 2022;12(2):861\u201372.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"2620_CR143","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519\u201330.","journal-title":"J Gen Physiol"},{"issue":"5","key":"2620_CR144","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2620_CR145","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","volume":"19","author":"C Qin","year":"2020","unstructured":"Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50.","journal-title":"Mol Cancer"},{"issue":"5516","key":"2620_CR146","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1126\/science.1058079","volume":"292","author":"T Pfeiffer","year":"2001","unstructured":"Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292(5516):504\u20137.","journal-title":"Science"},{"issue":"1","key":"2620_CR147","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-020-01765-x","volume":"39","author":"L Cao","year":"2020","unstructured":"Cao L, Wu J, Qu X, Sheng J, Cui M, Liu S, et al. Glycometabolic rearrangements\u2013aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. J Exp Clin Cancer Res. 2020;39(1):267.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2620_CR148","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/carcin\/bgae025","volume":"45","author":"S Yang","year":"2024","unstructured":"Yang S, Tang W, Azizian A, Gaedcke J, Ohara Y, Cawley H, et al. MIF\/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Carcinogenesis. 2024;45(8):582\u201394.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2620_CR149","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-021-00659-4","volume":"6","author":"S Wang","year":"2021","unstructured":"Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl","key":"2620_CR150","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.semcancer.2015.10.002","volume":"35","author":"MD Hirschey","year":"2015","unstructured":"Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015;35(Suppl):S129\u201350.","journal-title":"Semin Cancer Biol"},{"issue":"34","key":"2620_CR151","doi-asserted-by":"publisher","first-page":"56081","DOI":"10.18632\/oncotarget.9760","volume":"8","author":"M Anderson","year":"2017","unstructured":"Anderson M, Marayati R, Moffitt R, Yeh JJ. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget. 2017;8(34):56081\u201394.","journal-title":"Oncotarget"},{"issue":"1","key":"2620_CR152","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2019.10.012","volume":"31","author":"P Huangyang","year":"2020","unstructured":"Huangyang P, Li F, Lee P, Nissim I, Weljie AM, Mancuso A, et al. Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis. Cell Metab. 2020;31(1):174\u201388. e7.","journal-title":"Cell Metab"},{"issue":"2","key":"2620_CR153","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/0304-4165(66)90194-2","volume":"124","author":"M Ui","year":"1966","unstructured":"Ui M. A role of phosphofructokinase in pH-dependent regulation of glycolysis. Biochim Biophys Acta. 1966;124(2):310\u201322.","journal-title":"Biochim Biophys Acta"},{"issue":"5947","key":"2620_CR154","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.1174229","volume":"325","author":"J Yun","year":"2009","unstructured":"Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325(5947):1555\u20139.","journal-title":"Science"},{"issue":"2","key":"2620_CR155","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377\u201392.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2620_CR156","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41419-017-0158-5","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, Deng S, Liu M, Jin Y, Zhu S, Deng S, et al. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. Cell Death Dis. 2018;9(2):133.","journal-title":"Cell Death Dis"},{"issue":"16","key":"2620_CR157","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1016\/j.molcel.2022.06.005","volume":"82","author":"D He","year":"2022","unstructured":"He D, Feng H, Sundberg B, Yang J, Powers J, Christian AH, et al. Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Mol Cell. 2022;82(16):3045\u2013e6011.","journal-title":"Mol Cell"},{"key":"2620_CR158","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40170-018-0188-1","volume":"6","author":"AL Hillis","year":"2018","unstructured":"Hillis AL, Lau AN, Devoe CX, Dayton TL, Danai LV, Di Vizio D, et al. PKM2 is not required for pancreatic ductal adenocarcinoma. Cancer Metab. 2018;6:17.","journal-title":"Cancer Metab"},{"issue":"3","key":"2620_CR159","first-page":"881","volume":"52","author":"M Yokoyama","year":"2018","unstructured":"Yokoyama M, Tanuma N, Shibuya R, Shiroki T, Abue M, Yamamoto K, et al. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. Int J Oncol. 2018;52(3):881\u201391.","journal-title":"Int J Oncol"},{"issue":"12","key":"2620_CR160","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.bbamcr.2018.10.005","volume":"1865","author":"G Butera","year":"2018","unstructured":"Butera G, Pacchiana R, Mullappilly N, Margiotta M, Bruno S, Conti P, et al. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochim Biophys Acta Mol Cell Res. 2018;1865(12):1914\u201323.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1","key":"2620_CR161","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40880-019-0401-9","volume":"39","author":"F Shao","year":"2019","unstructured":"Shao F, Yang X, Wang W, Wang J, Guo W, Feng X, et al. Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. Cancer Commun (Lond). 2019;39(1):54.","journal-title":"Cancer Commun (Lond)"},{"issue":"46","key":"2620_CR162","doi-asserted-by":"publisher","first-page":"23264","DOI":"10.1073\/pnas.1914557116","volume":"116","author":"CL Wen","year":"2019","unstructured":"Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, et al. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2019;116(46):23264\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2620_CR163","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-016-0385-8","volume":"10","author":"M Principe","year":"2017","unstructured":"Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, et al. Alpha-enolase (ENO1) controls alpha v\/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017;10(1):16.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2620_CR164","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2016.01.054","volume":"374","author":"S Ji","year":"2016","unstructured":"Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi S, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016;374(1):127\u201335.","journal-title":"Cancer Lett"},{"issue":"Pt 2","key":"2620_CR165","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2022.09.001","volume":"86","author":"A Comandatore","year":"2022","unstructured":"Comandatore A, Franczak M, Smolenski RT, Morelli L, Peters GJ, Giovannetti E. Lactate dehydrogenase and its clinical significance in pancreatic and thoracic cancers. Semin Cancer Biol. 2022;86(Pt 2):93\u2013100.","journal-title":"Semin Cancer Biol"},{"issue":"15","key":"2620_CR166","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19(15):3896\u2013904.","journal-title":"EMBO J"},{"issue":"3","key":"2620_CR167","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1159\/000494477","volume":"50","author":"DH Wu","year":"2018","unstructured":"Wu DH, Liang H, Lu SN, Wang H, Su ZL, Zhang L, et al. miR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism. Cell Physiol Biochem. 2018;50(3):924\u201335.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"2620_CR168","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/MPA.0000000000000571","volume":"45","author":"SC Kong","year":"2016","unstructured":"Kong SC, Nohr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I, et al. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells. Pancreas. 2016;45(7):1036\u201347.","journal-title":"Pancreas"},{"issue":"32","key":"2620_CR169","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1038\/onc.2017.71","volume":"36","author":"TH Dovmark","year":"2017","unstructured":"Dovmark TH, Saccomano M, Hulikova A, Alves F, Swietach P. Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells. Oncogene. 2017;36(32):4538\u201350.","journal-title":"Oncogene"},{"issue":"10","key":"2620_CR170","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1136\/gut.2009.181412","volume":"58","author":"W Schneiderhan","year":"2009","unstructured":"Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut. 2009;58(10):1391\u20138.","journal-title":"Gut"},{"issue":"1","key":"2620_CR171","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-024-02044-3","volume":"10","author":"H Wen","year":"2025","unstructured":"Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X, et al. Mitochondrial diseases: from molecular mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):9.","journal-title":"Signal Transduct Target Ther"},{"key":"2620_CR172","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.97422","author":"HK Schofield","year":"2018","unstructured":"Schofield HK, Zeller J, Espinoza C, Halbrook CJ, Del Vecchio A, Magnuson B, et al. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight. 2018;3(2). https:\/\/doi.org\/10.1172\/jci.insight.97422.","journal-title":"JCI Insight"},{"issue":"5","key":"2620_CR173","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","volume":"61","author":"X Li","year":"2016","unstructured":"Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, et al. Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Mol Cell. 2016;61(5):705\u201319.","journal-title":"Mol Cell"},{"issue":"10","key":"2620_CR174","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/1078-0432.CCR-13-2407","volume":"20","author":"J Cui","year":"2014","unstructured":"Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S, et al. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014;20(10):2595\u2013606.","journal-title":"Clin Cancer Res"},{"key":"2620_CR175","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.canlet.2019.03.024","volume":"452","author":"Q Hu","year":"2019","unstructured":"Hu Q, Qin Y, Ji S, Xu W, Liu W, Sun Q, et al. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Lett. 2019;452:226\u201336.","journal-title":"Cancer Lett"},{"issue":"7","key":"2620_CR176","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/carcin\/bgu097","volume":"35","author":"CM Sousa","year":"2014","unstructured":"Sousa CM, Kimmelman AC. The complex landscape of pancreatic cancer metabolism. Carcinogenesis. 2014;35(7):1441\u201350.","journal-title":"Carcinogenesis"},{"issue":"10","key":"2620_CR177","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1073\/pnas.1219555110","volume":"110","author":"F Guillaumond","year":"2013","unstructured":"Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezene P, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110(10):3919\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2620_CR178","doi-asserted-by":"publisher","first-page":"31146","DOI":"10.1038\/srep31146","volume":"6","author":"T Golias","year":"2016","unstructured":"Golias T, Papandreou I, Sun R, Kumar B, Brown NV, Swanson BJ, et al. Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep. 2016;6:31146.","journal-title":"Sci Rep"},{"issue":"1","key":"2620_CR179","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1158\/1078-0432.CCR-19-1543","volume":"26","author":"JM Karasinska","year":"2020","unstructured":"Karasinska JM, Topham JT, Kalloger SE, Jang GH, Denroche RE, Culibrk L, et al. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Clin Cancer Res. 2020;26(1):135\u201346.","journal-title":"Clin Cancer Res"},{"issue":"6486","key":"2620_CR180","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85\u20139.","journal-title":"Science"},{"issue":"1","key":"2620_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02426-0","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yang Z, Liu Y, Pei J, Li R, Yang Y. Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment. Lipids Health Dis. 2025;24(1):12.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"2620_CR182","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/carcin\/bgae011","volume":"45","author":"Y Ohara","year":"2024","unstructured":"Ohara Y, Craig AJ, Liu H, Yang S, Moreno P, Dorsey TH, et al. LMO3 is a suppressor of the basal-like\/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Carcinogenesis. 2024;45(7):475\u201386.","journal-title":"Carcinogenesis"},{"issue":"3","key":"2620_CR183","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1158\/2159-8290.CD-18-0567","volume":"9","author":"A Carrer","year":"2019","unstructured":"Carrer A, Trefely S, Zhao S, Campbell SL, Norgard RJ, Schultz KC, et al. Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis. Cancer Discov. 2019;9(3):416\u201335.","journal-title":"Cancer Discov"},{"issue":"6","key":"2620_CR184","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","volume":"9","author":"U Sen","year":"2023","unstructured":"Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer. 2023;9(6):480\u20139.","journal-title":"Trends Cancer"},{"key":"2620_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115591","volume":"167","author":"R Mallick","year":"2023","unstructured":"Mallick R, Bhowmik P, Duttaroy AK. Targeting fatty acid uptake and metabolism in cancer cells: a promising strategy for cancer treatment. Biomed Pharmacother. 2023;167:115591.","journal-title":"Biomed Pharmacother"},{"issue":"20","key":"2620_CR186","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","volume":"77","author":"S Tadros","year":"2017","unstructured":"Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J, et al. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Res. 2017;77(20):5503\u201317.","journal-title":"Cancer Res"},{"issue":"12","key":"2620_CR187","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cac2.12360","volume":"42","author":"X Yin","year":"2022","unstructured":"Yin X, Xu R, Song J, Ruze R, Chen Y, Wang C, et al. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Commun (Lond). 2022;42(12):1234\u201356.","journal-title":"Cancer Commun (Lond)"},{"issue":"7753","key":"2620_CR188","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41586-019-1095-5","volume":"568","author":"KHG Verschueren","year":"2019","unstructured":"Verschueren KHG, Blanchet C, Felix J, Dansercoer A, De Vos D, Bloch Y, et al. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle. Nature. 2019;568(7753):571\u20135.","journal-title":"Nature"},{"issue":"8068","key":"2620_CR189","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","volume":"642","author":"C Cheng","year":"2025","unstructured":"Cheng C, Hu J, Mannan R, He T, Bhattacharyya R, Magnuson B, et al. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Nature. 2025;642(8068):776\u201384.","journal-title":"Nature"},{"key":"2620_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.06.001","volume":"62","author":"IH McKillop","year":"2019","unstructured":"McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019;62:109336.","journal-title":"Cell Signal"},{"issue":"3","key":"2620_CR191","doi-asserted-by":"publisher","first-page":"578","DOI":"10.7150\/jca.21046","volume":"9","author":"S Jia","year":"2018","unstructured":"Jia S, Zhou L, Shen T, Zhou S, Ding G, Cao L. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. J Cancer. 2018;9(3):578\u201383.","journal-title":"J Cancer"},{"issue":"3","key":"2620_CR192","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41580-018-0085-z","volume":"20","author":"JA Olzmann","year":"2019","unstructured":"Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20(3):137\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"2620_CR193","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1158\/0008-5472.CAN-20-1255","volume":"80","author":"CN Rozeveld","year":"2020","unstructured":"Rozeveld CN, Johnson KM, Zhang L, Razidlo GL. KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL. Cancer Res. 2020;80(22):4932\u201345.","journal-title":"Cancer Res"},{"key":"2620_CR194","doi-asserted-by":"publisher","DOI":"10.3390\/nu10091289","author":"Y Ding","year":"2018","unstructured":"Ding Y, Mullapudi B, Torres C, Mascarinas E, Mancinelli G, Diaz AM, et al. Omega-3 fatty acids prevent early pancreatic carcinogenesis via repression of the AKT pathway. Nutrients. 2018;10(9). https:\/\/doi.org\/10.3390\/nu10091289.","journal-title":"Nutrients"},{"key":"2620_CR195","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.canlet.2018.08.006","volume":"435","author":"Y Ma","year":"2018","unstructured":"Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, et al. Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92\u2013100.","journal-title":"Cancer Lett"},{"key":"2620_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092477","author":"JS Lee","year":"2020","unstructured":"Lee JS, Oh SJ, Choi HJ, Kang JH, Lee SH, Ha JS, et al. ATP production relies on fatty acid oxidation rather than glycolysis in pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(9). https:\/\/doi.org\/10.3390\/cancers12092477.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2620_CR197","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41556-018-0122-3","volume":"20","author":"KC Patra","year":"2018","unstructured":"Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, et al. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018;20(7):811\u201322.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2620_CR198","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3892\/ol.2017.5821","volume":"13","author":"M Ji","year":"2017","unstructured":"Ji M, Jin A, Sun J, Cui X, Yang Y, Chen L, et al. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncol Lett. 2017;13(5):2996\u20133002.","journal-title":"Oncol Lett"},{"key":"2620_CR199","doi-asserted-by":"publisher","unstructured":"Williams D, Patel C, Murray K, Oldfield L, Small B, Barrera LN, et al. NQO1 as apredictor of response to adjuvant GemCap treatment for pancreatic cancer. J Natl Cancer Inst. 2025. https:\/\/doi.org\/10.1093\/jnci\/djaf345.","DOI":"10.1093\/jnci\/djaf345"},{"issue":"5","key":"2620_CR200","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3724\/abbs.2023066","volume":"55","author":"R Xu","year":"2023","unstructured":"Xu R, Liu Y, Ma L, Sun Y, Liu H, Yang Y, et al. NQO1\/CPT1A promotes the progression of pancreatic adenocarcinoma via fatty acid oxidation. Acta Biochim Biophys Sin (Shanghai). 2023;55(5):758\u201368.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"2620_CR201","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s42003-021-02508-0","volume":"4","author":"A Acier","year":"2021","unstructured":"Acier A, Godard M, Gassiot F, Finetti P, Rubis M, Nowak J, et al. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol. 2021;4(1):987.","journal-title":"Commun Biol"},{"issue":"2","key":"2620_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2024.159578","volume":"1870","author":"T Daya","year":"2025","unstructured":"Daya T, Breytenbach A, Gu L, Kaur M. Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies. Biochim Biophys Acta Mol Cell Biol Lipids. 2025;1870(2):159578.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2620_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11060332","author":"S Endo","year":"2021","unstructured":"Endo S, Matsunaga T, Nishinaka T. The role of AKR1B10 in physiology and pathophysiology. Metabolites. 2021;11(6). https:\/\/doi.org\/10.3390\/metabo11060332.","journal-title":"Metabolites"},{"issue":"6","key":"2620_CR204","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s13277-015-3047-5","volume":"36","author":"Y Sun","year":"2015","unstructured":"Sun Y, He W, Luo M, Zhou Y, Chang G, Ren W, et al. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumour Biol. 2015;36(6):4133\u201341.","journal-title":"Tumour Biol"},{"issue":"1","key":"2620_CR205","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbrc.2017.05.023","volume":"488","author":"S Siqingaowa, Sekar","year":"2017","unstructured":"Siqingaowa, Sekar S, Gopalakrishnan V, Taghibiglou C. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochem Biophys Res Commun. 2017;488(1):136\u201340.","journal-title":"Biochem Biophys Res Commun"},{"issue":"50","key":"2620_CR206","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1038\/onc.2016.168","volume":"35","author":"J Li","year":"2016","unstructured":"Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, Chen S, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;35(50):6378\u201388.","journal-title":"Oncogene"},{"key":"2620_CR207","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192389","author":"TE Oni","year":"2020","unstructured":"Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, et al. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. J Exp Med. 2020;217(9). https:\/\/doi.org\/10.1084\/jem.20192389.","journal-title":"J Exp Med"},{"issue":"4","key":"2620_CR208","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","volume":"38","author":"L Gabitova-Cornell","year":"2020","unstructured":"Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, et al. Cholesterol Pathway Inhibition Induces TGF-beta Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell. 2020;38(4):567\u201383. e11.","journal-title":"Cancer Cell"},{"issue":"1","key":"2620_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01760-1","volume":"22","author":"X Liu","year":"2024","unstructured":"Liu X, Ren B, Ren J, Gu M, You L, Zhao Y. The significant role of amino acid metabolic reprogramming in cancer. Cell Commun Signal. 2024;22(1):380.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"2620_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01569-3","volume":"8","author":"ZN Ling","year":"2023","unstructured":"Ling ZN, Jiang YF, Ru JN, Lu JH, Ding B, Wu J. Amino acid metabolism in health and disease. Signal Transduct Target Ther. 2023;8(1):345.","journal-title":"Signal Transduct Target Ther"},{"issue":"7617","key":"2620_CR211","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature19084","volume":"536","author":"CM Sousa","year":"2016","unstructured":"Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536(7617):479\u201383.","journal-title":"Nature"},{"issue":"5","key":"2620_CR212","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.celrep.2019.09.056","volume":"29","author":"AJ Bott","year":"2019","unstructured":"Bott AJ, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang YP, et al. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Rep. 2019;29(5):1287\u2013e986.","journal-title":"Cell Rep"},{"issue":"7443","key":"2620_CR213","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101\u20135.","journal-title":"Nature"},{"issue":"1","key":"2620_CR214","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1038\/s41467-021-24859-2","volume":"12","author":"DM Kremer","year":"2021","unstructured":"Kremer DM, Nelson BS, Lin L, Yarosz EL, Halbrook CJ, Kerk SA, et al. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nat Commun. 2021;12(1):4860.","journal-title":"Nat Commun"},{"key":"2620_CR215","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2017.04.029","volume":"400","author":"J Abrego","year":"2017","unstructured":"Abrego J, Gunda V, Vernucci E, Shukla SK, King RJ, Dasgupta A, et al. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett. 2017;400:37\u201346.","journal-title":"Cancer Lett"},{"issue":"4","key":"2620_CR216","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.molcel.2016.09.028","volume":"64","author":"YP Wang","year":"2016","unstructured":"Wang YP, Zhou W, Wang J, Huang X, Zuo Y, Wang TS, et al. Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer. Mol Cell. 2016;64(4):673\u201387.","journal-title":"Mol Cell"},{"issue":"1","key":"2620_CR217","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbcan.2018.04.011","volume":"1870","author":"DE Biancur","year":"2018","unstructured":"Biancur DE, Kimmelman AC. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochim Biophys Acta Rev Cancer. 2018;1870(1):67\u201375.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"2620_CR218","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","volume":"1863","author":"YD Bhutia","year":"2016","unstructured":"Bhutia YD, Ganapathy V. Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta. 2016;1863(10):2531\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2620_CR219","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1535-7163.MCT-14-0420","volume":"14","author":"HQ Ju","year":"2015","unstructured":"Ju HQ, Gocho T, Aguilar M, Wu M, Zhuang ZN, Fu J, et al. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Mol Cancer Ther. 2015;14(3):788\u201398.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2620_CR220","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41556-019-0407-1","volume":"21","author":"VM Wang","year":"2019","unstructured":"Wang VM, Ferreira RMM, Almagro J, Evan T, Legrave N, Zaw Thin M, et al. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nat Cell Biol. 2019;21(11):1425\u201335.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2620_CR221","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13105-019-00716-1","volume":"76","author":"H Wang","year":"2020","unstructured":"Wang H, Li QF, Chow HY, Choi SC, Leung YC. Arginine deprivation inhibits pancreatic cancer cell migration, invasion and EMT via the down regulation of Snail, Slug, Twist, and MMP1\/9. J Physiol Biochem. 2020;76(1):73\u201383.","journal-title":"J Physiol Biochem"},{"issue":"41","key":"2620_CR222","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044904","volume":"104","author":"Y Gao","year":"2025","unstructured":"Gao Y, Yang L, Wang X. Tryptophan metabolism in pancreatic cancer: a review. Medicine (Baltimore). 2025;104(41):e44904.","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"2620_CR223","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1158\/0008-5472.CAN-12-0057","volume":"72","author":"BL Lampson","year":"2012","unstructured":"Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, et al. Targeting eNOS in pancreatic cancer. Cancer Res. 2012;72(17):4472\u201382.","journal-title":"Cancer Res"},{"issue":"5","key":"2620_CR224","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten M, Nollen EAA, Rohrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379\u2013401.","journal-title":"Nat Rev Drug Discov"},{"issue":"7650","key":"2620_CR225","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature22056","volume":"544","author":"ODK Maddocks","year":"2017","unstructured":"Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544(7650):372\u20136.","journal-title":"Nature"},{"key":"2620_CR226","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41420-020-00341-8","volume":"6","author":"L Burke","year":"2020","unstructured":"Burke L, Guterman I, Palacios Gallego R, Britton RG, Burschowsky D, Tufarelli C, et al. The Janus-like role of proline metabolism in cancer. Cell Death Discov. 2020;6:104.","journal-title":"Cell Death Discov"},{"key":"2620_CR227","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/ncomms16031","volume":"8","author":"O Olivares","year":"2017","unstructured":"Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun. 2017;8:16031.","journal-title":"Nat Commun"},{"issue":"6","key":"2620_CR228","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","volume":"174","author":"JS Lee","year":"2018","unstructured":"Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell. 2018;174(6):1559\u2013e7022.","journal-title":"Cell"},{"issue":"6304","key":"2620_CR229","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aaf5171","volume":"353","author":"JR Mayers","year":"2016","unstructured":"Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science. 2016;353(6304):1161\u20135.","journal-title":"Science"},{"issue":"13","key":"2620_CR230","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1016\/j.celrep.2017.12.002","volume":"21","author":"M Yue","year":"2017","unstructured":"Yue M, Jiang J, Gao P, Liu H, Qing G. Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis. Cell Rep. 2017;21(13):3819\u201332.","journal-title":"Cell Rep"},{"issue":"10","key":"2620_CR231","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nm.3686","volume":"20","author":"JR Mayers","year":"2014","unstructured":"Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193\u20138.","journal-title":"Nat Med"},{"issue":"7639","key":"2620_CR232","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature21052","volume":"542","author":"P Dey","year":"2017","unstructured":"Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017;542(7639):119\u201323.","journal-title":"Nature"},{"issue":"4","key":"2620_CR233","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41556-024-01372-4","volume":"26","author":"D Murthy","year":"2024","unstructured":"Murthy D, Attri KS, Shukla SK, Thakur R, Chaika NV, He C, et al. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Nat Cell Biol. 2024;26(4):613\u201327.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2620_CR234","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10555-021-10004-4","volume":"40","author":"HB Andersen","year":"2021","unstructured":"Andersen HB, Ialchina R, Pedersen SF, Czaplinska D. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets. Cancer Metastasis Rev. 2021;40(4):1093\u2013114.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2620_CR235","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3753","volume":"49","author":"OG McDonald","year":"2017","unstructured":"McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017;49(3):367\u201376.","journal-title":"Nat Genet"},{"issue":"6","key":"2620_CR236","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.7150\/ijbs.69526","volume":"18","author":"S Chen","year":"2022","unstructured":"Chen S, Ning B, Song J, Yang Z, Zhou L, Chen Z, et al. Enhanced pentose phosphate pathway activity promotes pancreatic ductal adenocarcinoma progression via activating YAP\/MMP1 axis under chronic acidosis. Int J Biol Sci. 2022;18(6):2304\u201316.","journal-title":"Int J Biol Sci"},{"issue":"16","key":"2620_CR237","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1016\/j.jmb.2016.05.028","volume":"428","author":"CM Ferrer","year":"2016","unstructured":"Ferrer CM, Sodi VL, Reginato MJ. O-GlcNAcylation in cancer biology: linking metabolism and signaling. J Mol Biol. 2016;428(16):3282\u201394.","journal-title":"J Mol Biol"},{"key":"2620_CR238","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ceb.2014.10.001","volume":"33","author":"MS Denzel","year":"2015","unstructured":"Denzel MS, Antebi A. Hexosamine pathway and (ER) protein quality control. Curr Opin Cell Biol. 2015;33:14\u20138.","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"2620_CR239","first-page":"1556","volume":"12","author":"YS Hsu","year":"2022","unstructured":"Hsu YS, Wu PJ, Jeng YM, Hu CM, Lee WH. Differential effects of glucose and N-acetylglucosamine on genome instability. Am J Cancer Res. 2022;12(4):1556\u201376.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2620_CR240","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ygeno.2021.01.010","volume":"113","author":"C Yang","year":"2021","unstructured":"Yang C, Hu JF, Zhan Q, Wang ZW, Li G, Pan JJ, et al. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Genomics. 2021;113(2):827\u201342.","journal-title":"Genomics"},{"issue":"21","key":"2620_CR241","doi-asserted-by":"publisher","first-page":"15121","DOI":"10.1074\/jbc.M113.470047","volume":"288","author":"Z Ma","year":"2013","unstructured":"Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappaB activity in pancreatic cancer cells. J Biol Chem. 2013;288(21):15121\u201330.","journal-title":"J Biol Chem"},{"issue":"12","key":"2620_CR242","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.7150\/thno.32615","volume":"9","author":"NS Sharma","year":"2019","unstructured":"Sharma NS, Gupta VK, Dauer P, Kesh K, Hadad R, Giri B, et al. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Theranostics. 2019;9(12):3410\u201324.","journal-title":"Theranostics"},{"issue":"10","key":"2620_CR243","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41418-022-00984-3","volume":"29","author":"X He","year":"2022","unstructured":"He X, Li Y, Chen Q, Zheng L, Lou J, Lin C, et al. O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGgamma interaction. Cell Death Differ. 2022;29(10):1970\u201381.","journal-title":"Cell Death Differ"},{"issue":"6","key":"2620_CR244","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.cmet.2019.02.005","volume":"29","author":"CM Hu","year":"2019","unstructured":"Hu CM, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, et al. High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells. Cell Metab. 2019;29(6):1334\u2013e4910.","journal-title":"Cell Metab"},{"issue":"9","key":"2620_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05259-w","volume":"13","author":"YH Liu","year":"2022","unstructured":"Liu YH, Hu CM, Hsu YS, Lee WH. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13(9):817.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2620_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07517-z","volume":"16","author":"T Pienkowski","year":"2025","unstructured":"Pienkowski T, Wawrzak-Pienkowska K, Tankiewicz-Kwedlo A, Ciborowski M, Kurek K, Pawlak D. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2025;16(1):227.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2620_CR247","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-024-02050-7","volume":"23","author":"Y Fu","year":"2024","unstructured":"Fu Y, Tao J, Liu T, Liu Y, Qiu J, Su D, et al. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. Mol Cancer. 2024;23(1):140.","journal-title":"Mol Cancer"},{"issue":"9","key":"2620_CR248","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14(9):587.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2620_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188888","volume":"1878","author":"V Bhardwaj","year":"2023","unstructured":"Bhardwaj V, Zhang X, Pandey V, Garg M. High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells. Biochim Biophys Acta Rev Cancer. 2023;1878(3):188888.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2620_CR250","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y, et al. Lactate and lactylation in cancer. Signal Transduct Target Ther. 2025;10(1):38.","journal-title":"Signal Transduct Target Ther"},{"key":"2620_CR251","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2023.06.006","volume":"71\u201372","author":"DSR Bandi","year":"2023","unstructured":"Bandi DSR, Sarvesh S, Farran B, Nagaraju GP, El-Rayes BF. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: insights and future directions. Cytokine Growth Factor Rev. 2023;71\u201372:26\u201339.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2620_CR252","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0858-1","volume":"17","author":"B Ren","year":"2018","unstructured":"Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108.","journal-title":"Mol Cancer"},{"key":"2620_CR253","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303.","journal-title":"Front Immunol"},{"key":"2620_CR254","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80721","author":"RE Menjivar","year":"2023","unstructured":"Menjivar RE, Nwosu ZC, Du W, Donahue KL, Hong HS, Espinoza C, et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Elife. 2023;12. https:\/\/doi.org\/10.7554\/eLife.80721.","journal-title":"Elife"},{"issue":"12","key":"2620_CR255","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","volume":"5","author":"K Mehla","year":"2019","unstructured":"Mehla K, Singh PK. Metabolic Regulation of Macrophage Polarization in Cancer. Trends Cancer. 2019;5(12):822\u201334.","journal-title":"Trends Cancer"},{"issue":"5","key":"2620_CR256","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41419-018-0486-0","volume":"9","author":"H Ye","year":"2018","unstructured":"Ye H, Zhou Q, Zheng S, Li G, Lin Q, Wei L, et al. Tumor-associated macrophages promote progression and the Warburg effect via CCL18\/NF-kB\/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death Dis. 2018;9(5):453.","journal-title":"Cell Death Dis"},{"key":"2620_CR257","doi-asserted-by":"publisher","first-page":"216784","DOI":"10.1016\/j.canlet.2024.216784","volume":"588","author":"Z Zhong","year":"2024","unstructured":"Zhong Z, Yang K, Li Y, Zhou S, Yao H, Zhao Y, et al. Tumor-associated macrophages drive glycolysis through the IL-8\/STAT3\/GLUT3 signaling pathway in pancreatic cancer progression. Cancer Lett. 2024;588:216784.","journal-title":"Cancer Lett"},{"key":"2620_CR258","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395786","volume":"15","author":"B Xu","year":"2024","unstructured":"Xu B, Liu Y, Li N, Geng Q. Lactate and lactylation in macrophage metabolic reprogramming: current progress and outstanding issues. Front Immunol. 2024;15:1395786.","journal-title":"Front Immunol"},{"issue":"42","key":"2620_CR259","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36(42):5829\u201339.","journal-title":"Oncogene"},{"issue":"7","key":"2620_CR260","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2620_CR261","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00262-022-03340-z","volume":"72","author":"PF Fiore","year":"2023","unstructured":"Fiore PF, Di Pace AL, Conti LA, Tumino N, Besi F, Scaglione S, et al. Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers. Cancer Immunol Immunother. 2023;72(6):1417\u201328.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2620_CR262","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab. 2017;25(6):1282\u201393. e7.","journal-title":"Cell Metab"},{"issue":"4","key":"2620_CR263","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","volume":"18","author":"W Yang","year":"2021","unstructured":"Yang W, Cong Y. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol. 2021;18(4):866\u201377.","journal-title":"Cell Mol Immunol"},{"issue":"24","key":"2620_CR264","doi-asserted-by":"publisher","first-page":"eadn6331","DOI":"10.1126\/sciadv.adn6331","volume":"10","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Han F, Wu Z, Wang B, Chen X, Boulouis C, et al. MAIT cell activation and recruitment in inflammation and tissue damage in acute appendicitis. Sci Adv. 2024;10(24):eadn6331.","journal-title":"Sci Adv"},{"issue":"1","key":"2620_CR265","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"K Hou","year":"2022","unstructured":"Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2620_CR266","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","volume":"31","author":"YR Li","year":"2023","unstructured":"Li YR, Zhou K, Wilson M, Kramer A, Zhu Y, Dawson N, et al. Mucosal-associated invariant T cells for cancer immunotherapy. Mol Ther. 2023;31(3):631\u201346.","journal-title":"Mol Ther"},{"issue":"11","key":"2620_CR267","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/carcin\/bgae063","volume":"45","author":"IC McCabe","year":"2024","unstructured":"McCabe IC, Peng XL, Kearney JF, Yeh JJ. Cafomics: convergence to translation for precision stroma approaches. Carcinogenesis. 2024;45(11):817\u201322.","journal-title":"Carcinogenesis"},{"key":"2620_CR268","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113244","author":"R Perez-Tomas","year":"2020","unstructured":"Perez-Tomas R, Perez-Guillen I. Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers (Basel). 2020;12(11). https:\/\/doi.org\/10.3390\/cancers12113244.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2620_CR269","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/abbs\/gmw097","volume":"48","author":"C Liang","year":"2016","unstructured":"Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2016;48(11):969\u201379.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"23","key":"2620_CR270","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","volume":"8","author":"S Pavlides","year":"2009","unstructured":"Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984\u20134001.","journal-title":"Cell Cycle"},{"issue":"8","key":"2620_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06930-0","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu H, Fu M, Wu M, Cao Z, Zhang Q, Liu Z. Emerging mechanisms and promising approaches in pancreatic cancer metabolism. Cell Death Dis. 2024;15(8):553.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2620_CR272","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/2159-8290.CD-18-1212","volume":"9","author":"FR Auciello","year":"2019","unstructured":"Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 2019;9(5):617\u201327.","journal-title":"Cancer Discov"},{"issue":"22","key":"2620_CR273","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-19-0960","volume":"79","author":"S Dalin","year":"2019","unstructured":"Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, et al. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res. 2019;79(22):5723\u201333.","journal-title":"Cancer Res"},{"issue":"2","key":"2620_CR274","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2015.06.017","volume":"162","author":"W Palm","year":"2015","unstructured":"Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. Cell. 2015;162(2):259\u201370.","journal-title":"Cell"},{"issue":"16","key":"2620_CR275","doi-asserted-by":"publisher","first-page":"eadf9284","DOI":"10.1126\/sciadv.adf9284","volume":"9","author":"S Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay S, Encarnacion-Rosado J, Lin EY, Sohn ASW, Zhang H, Mancias JD, et al. Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. Sci Adv. 2023;9(16):eadf9284.","journal-title":"Sci Adv"},{"issue":"4","key":"2620_CR276","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.7150\/thno.89805","volume":"14","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Fang S, Fan B, Xu K, Xu L, Wang L, et al. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer. Theranostics. 2024;14(4):1683\u2013700.","journal-title":"Theranostics"},{"key":"2620_CR277","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.808859","volume":"10","author":"M Jin","year":"2022","unstructured":"Jin M, Cao W, Chen B, Xiong M, Cao G. Tumor-derived lactate creates a favorable niche for tumor via supplying energy source for tumor and modulating the tumor microenvironment. Front Cell Dev Biol. 2022;10:808859.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"2620_CR278","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1101\/gad.2016111","volume":"25","author":"S Yang","year":"2011","unstructured":"Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717\u201329.","journal-title":"Genes Dev"},{"issue":"1","key":"2620_CR279","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1138-4","volume":"19","author":"X Li","year":"2020","unstructured":"Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12.","journal-title":"Mol Cancer"},{"issue":"2","key":"2620_CR280","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-020-01039-5","volume":"124","author":"M Piffoux","year":"2021","unstructured":"Piffoux M, Eriau E, Cassier PA. Autophagy as a therapeutic target in pancreatic cancer. Br J Cancer. 2021;124(2):333\u201344.","journal-title":"Br J Cancer"},{"issue":"3","key":"2620_CR281","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2159-8290.CD-17-0952","volume":"8","author":"A Yang","year":"2018","unstructured":"Yang A, Herter-Sprie G, Zhang H, Lin EY, Biancur D, Wang X, et al. Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Cancer Discov. 2018;8(3):276\u201387.","journal-title":"Cancer Discov"},{"issue":"6","key":"2620_CR282","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41591-020-0947-8","volume":"26","author":"KL Bryant","year":"2020","unstructured":"Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, et al. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2020;26(6):982.","journal-title":"Nat Med"},{"issue":"4","key":"2620_CR283","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","volume":"25","author":"CG Kinsey","year":"2019","unstructured":"Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, et al. Protective autophagy elicited by RAF\u2013>MEK\u2013>ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019;25(4):620\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"2620_CR284","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2015.99","volume":"35","author":"VW Rebecca","year":"2016","unstructured":"Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene. 2016;35(1):1\u201311.","journal-title":"Oncogene"},{"issue":"7479","key":"2620_CR285","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nature12865","volume":"504","author":"MT Rosenfeldt","year":"2013","unstructured":"Rosenfeldt MT, O\u2019Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296\u2013300. https:\/\/doi.org\/10.1038\/nature12865.","journal-title":"Nature"},{"issue":"8","key":"2620_CR286","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/2159-8290.CD-14-0362","volume":"4","author":"A Yang","year":"2014","unstructured":"Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 2014;4(8):905\u201313.","journal-title":"Cancer Discov"},{"issue":"7565","key":"2620_CR287","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","volume":"524","author":"RM Perera","year":"2015","unstructured":"Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015;524(7565):361\u20135. https:\/\/doi.org\/10.1038\/nature14587Missing.","journal-title":"Nature"},{"issue":"9","key":"2620_CR288","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00535-022-01889-1","volume":"57","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Iwadate D, Kato H, Nakai Y, Tateishi K, Fujishiro M. Targeting autophagy as a therapeutic strategy against pancreatic cancer. J Gastroenterol. 2022;57(9):603\u201318.","journal-title":"J Gastroenterol"},{"key":"2620_CR289","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1038\/ncomms9048","volume":"6","author":"PM Wong","year":"2015","unstructured":"Wong PM, Feng Y, Wang J, Shi R, Jiang X. Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A. Nat Commun. 2015;6:8048.","journal-title":"Nat Commun"},{"issue":"8","key":"2620_CR290","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s43018-022-00426-6","volume":"3","author":"M Yuan","year":"2022","unstructured":"Yuan M, Tu B, Li H, Pang H, Zhang N, Fan M, et al. Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth. Nat Cancer. 2022;3(8):945\u201360. https:\/\/doi.org\/10.1038\/s43018-022-00426-6.","journal-title":"Nat Cancer"},{"issue":"1","key":"2620_CR291","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1186\/s12967-025-07164-0","volume":"23","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Cao Z, Yan S, Chen B, Wu H, Cao H, et al. Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells. J Transl Med. 2025;23(1):1118.","journal-title":"J Transl Med"},{"key":"2620_CR292","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11\u201321.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"2620_CR293","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41420-024-01933-4","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Aoki H, Umezawa K, Kranrod J, Miyazaki N, Oshima T, et al. Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells. Cell Death Discov. 2024;10(1):166.","journal-title":"Cell Death Discov"},{"issue":"2","key":"2620_CR294","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nm.4256","volume":"23","author":"SM Davidson","year":"2017","unstructured":"Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med. 2017;23(2):235\u201341.","journal-title":"Nat Med"},{"issue":"3","key":"2620_CR295","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","volume":"75","author":"JJ Kamphorst","year":"2015","unstructured":"Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75(3):544\u201353.","journal-title":"Cancer Res"},{"issue":"1","key":"2620_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14928-3","volume":"11","author":"V Jayashankar","year":"2020","unstructured":"Jayashankar V, Edinger AL. Macropinocytosis confers resistance to therapies targeting cancer anabolism. Nat Commun. 2020;11(1):1121.","journal-title":"Nat Commun"},{"issue":"7451","key":"2620_CR297","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633\u20137.","journal-title":"Nature"},{"issue":"3","key":"2620_CR298","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.devcel.2019.05.043","volume":"50","author":"SW Lee","year":"2019","unstructured":"Lee SW, Zhang Y, Jung M, Cruz N, Alas B, Commisso C. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis. Dev Cell. 2019;50(3):381\u201392. e5. https:\/\/doi.org\/10.1016\/j.devcel.2019.05.043.","journal-title":"Dev Cell"},{"issue":"3","key":"2620_CR299","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2017.09.046","volume":"171","author":"GA Wyant","year":"2017","unstructured":"Wyant GA, Abu-Remaileh M, Wolfson RL, Chen WW, Freinkman E, Danai LV, et al. mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient. Cell. 2017;171(3):642\u201354. e12. https:\/\/doi.org\/10.1016\/j.cell.2017.09.046.","journal-title":"Cell"},{"key":"2620_CR300","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","volume":"43","author":"C He","year":"2009","unstructured":"He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67\u201393.","journal-title":"Annu Rev Genet"},{"issue":"7","key":"2620_CR301","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0119","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Recouvreux MV, Jung M, Galenkamp KMO, Li Y, Zagnitko O, et al. Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2\/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness. Cancer Discov. 2021;11(7):1808\u201325.","journal-title":"Cancer Discov"},{"issue":"9","key":"2620_CR302","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.ccell.2025.06.021","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ling L, Murad R, Maganti S, Manceau A, Hetrick HA, et al. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. Cancer Cell. 2025;43(9):1677\u2013e9615.","journal-title":"Cancer Cell"},{"key":"2620_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124128","author":"P Espiau-Romera","year":"2020","unstructured":"Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P. Molecular and metabolic subtypes correspondence for pancreatic ductal adenocarcinoma classification. J Clin Med. 2020;9(12). https:\/\/doi.org\/10.3390\/jcm9124128.","journal-title":"J Clin Med"},{"issue":"32","key":"2620_CR304","doi-asserted-by":"publisher","first-page":"E4410","DOI":"10.1073\/pnas.1501605112","volume":"112","author":"A Daemen","year":"2015","unstructured":"Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci U S A. 2015;112(32):E4410\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2620_CR305","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500\u20133.","journal-title":"Nat Med"},{"issue":"1","key":"2620_CR306","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-19-2926","volume":"26","author":"K Mehla","year":"2020","unstructured":"Mehla K, Singh PK. Metabolic subtyping for novel personalized therapies against pancreatic cancer. Clin Cancer Res. 2020;26(1):6\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2620_CR307","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(1):71-87 e7.","journal-title":"Cancer Cell"},{"key":"2620_CR308","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108946","volume":"277","author":"Y Ohara","year":"2026","unstructured":"Ohara Y, Liu H, Moreno P, Suzuki S, Hussain SP. Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: insights into tumor heterogeneity and clinical implications. Pharmacol Ther. 2026;277:108946.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2620_CR309","doi-asserted-by":"publisher","first-page":"101162","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4(9):101162.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2620_CR310","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41467-018-04383-6","volume":"9","author":"G Lomberk","year":"2018","unstructured":"Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9(1):1978.","journal-title":"Nat Commun"},{"issue":"3","key":"2620_CR311","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ijc.34960","volume":"155","author":"Y Ohara","year":"2024","unstructured":"Ohara Y, Liu H, Craig AJ, Yang S, Moreno P, Dorsey TH, et al. ELAPOR1 induces the classical\/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. Int J Cancer. 2024;155(3):569\u201381.","journal-title":"Int J Cancer"},{"issue":"11","key":"2620_CR312","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/carcin\/bgae056","volume":"45","author":"P Moreno","year":"2024","unstructured":"Moreno P, Ohara Y, Craig AJ, Liu H, Yang S, Dorsey TH, et al. ADRA2A promotes the classical\/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Carcinogenesis. 2024;45(11):845\u201356.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2620_CR313","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2016.08.023","volume":"382","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Duan Q, Zhao H, Liu T, Wu H, Shen Q, et al. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox\/ROS\/NF-kappaB\/STAT3 signaling cascade. Cancer Lett. 2016;382(1):53\u201363.","journal-title":"Cancer Lett"},{"key":"2620_CR314","doi-asserted-by":"publisher","DOI":"10.1002\/med.21761","author":"M Garg","year":"2020","unstructured":"Garg M, Shanmugam MK, Bhardwaj V, Goel A, Gupta R, Sharma A, et al. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Med Res Rev. 2020. https:\/\/doi.org\/10.1002\/med.21761.","journal-title":"Med Res Rev"},{"issue":"16","key":"2620_CR315","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-17-0015","volume":"77","author":"M Zarei","year":"2017","unstructured":"Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, et al. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Res. 2017;77(16):4460\u201371.","journal-title":"Cancer Res"},{"issue":"34","key":"2620_CR316","doi-asserted-by":"publisher","first-page":"13787","DOI":"10.1073\/pnas.1203339109","volume":"109","author":"NV Chaika","year":"2012","unstructured":"Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A. 2012;109(34):13787\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2620_CR317","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1038\/s41598-017-08436-6","volume":"7","author":"R Chen","year":"2017","unstructured":"Chen R, Lai LA, Sullivan Y, Wong M, Wang L, Riddell J, et al. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep. 2017;7(1):7950.","journal-title":"Sci Rep"},{"issue":"1","key":"2620_CR318","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","volume":"37","author":"M Feng","year":"2018","unstructured":"Feng M, Xiong G, Cao Z, Yang G, Zheng S, Qiu J, et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):274.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2620_CR319","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.1038\/s41467-024-52978-z","volume":"15","author":"V de Laat","year":"2024","unstructured":"de Laat V, Topal H, Spotbeen X, Talebi A, Dehairs J, Idkowiak J, et al. Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer. Nat Commun. 2024;15(1):8540.","journal-title":"Nat Commun"},{"issue":"11","key":"2620_CR320","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-23-1421","volume":"30","author":"ES Carpenter","year":"2024","unstructured":"Carpenter ES, Kadiyala P, Elhossiny AM, Kemp SB, Li J, Steele NG, et al. KRT17high\/CXCL8\u2009+\u2009Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Clin Cancer Res. 2024;30(11):2497\u2013513.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2620_CR321","doi-asserted-by":"publisher","first-page":"101234","DOI":"10.1016\/j.xcrm.2023.101234","volume":"4","author":"R Tang","year":"2023","unstructured":"Tang R, Xu J, Wang W, Meng Q, Shao C, Zhang Y, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Rep Med. 2023;4(10):101234.","journal-title":"Cell Rep Med"},{"issue":"9","key":"2620_CR322","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","volume":"4","author":"X Zhou","year":"2023","unstructured":"Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat Cancer. 2023;4(9):1362\u201381.","journal-title":"Nat Cancer"},{"issue":"2","key":"2620_CR323","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.xcrm.2024.101411","volume":"5","author":"V Ruta","year":"2024","unstructured":"Ruta V, Naro C, Pieraccioli M, Leccese A, Archibugi L, Cesari E, et al. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Cell Rep Med. 2024;5(2):101411.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2620_CR324","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.gastro.2020.09.043","volume":"160","author":"SB Dreyer","year":"2021","unstructured":"Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, et al. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology. 2021;160(1):362\u201377. e13.","journal-title":"Gastroenterology"},{"issue":"41","key":"2620_CR325","doi-asserted-by":"publisher","first-page":"24760","DOI":"10.1074\/jbc.M115.668707","volume":"290","author":"AD James","year":"2015","unstructured":"James AD, Patel W, Butt Z, Adiamah M, Dakhel R, Latif A, et al. The Plasma Membrane Calcium Pump in Pancreatic Cancer Cells Exhibiting the Warburg Effect Relies on Glycolytic ATP. J Biol Chem. 2015;290(41):24760\u201371.","journal-title":"J Biol Chem"},{"issue":"2","key":"2620_CR326","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2620_CR327","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1038\/cddis.2012.24","volume":"3","author":"L Goldberg","year":"2012","unstructured":"Goldberg L, Israeli R, Kloog Y. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis. 2012;3(3):e284.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2620_CR328","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.bbrc.2018.05.041","volume":"501","author":"K Ishino","year":"2018","unstructured":"Ishino K, Kudo M, Peng WX, Kure S, Kawahara K, Teduka K, et al. 2-deoxy-d-glucose increases GFAT1 phosphorylation resulting in endoplasmic reticulum-related apoptosis via disruption of protein N-glycosylation in pancreatic cancer cells. Biochem Biophys Res Commun. 2018;501(3):668\u201373.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2620_CR329","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.freeradbiomed.2007.08.032","volume":"44","author":"MC Coleman","year":"2008","unstructured":"Coleman MC, Asbury CR, Daniels D, Du J, Aykin-Burns N, Smith BJ, et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med. 2008;44(3):322\u201331.","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"2620_CR330","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1158\/0008-5472.CAN-20-3792","volume":"81","author":"L Yan","year":"2021","unstructured":"Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, et al. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Res. 2021;81(15):4054\u201365.","journal-title":"Cancer Res"},{"key":"2620_CR331","doi-asserted-by":"publisher","first-page":"115286","DOI":"10.1016\/j.ejmech.2023.115286","volume":"254","author":"A Galbiati","year":"2023","unstructured":"Galbiati A, Bova S, Pacchiana R, Borsari C, Persico M, Zana A, et al. Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells. Eur J Med Chem. 2023;254:115286.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"2620_CR332","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41416-019-0675-3","volume":"122","author":"AD James","year":"2020","unstructured":"James AD, Richardson DA, Oh IW, Sritangos P, Attard T, Barrett L, et al. Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2). Br J Cancer. 2020;122(2):266\u201378.","journal-title":"Br J Cancer"},{"issue":"8","key":"2620_CR333","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jjco\/hyac074","volume":"52","author":"Y Wada","year":"2022","unstructured":"Wada Y, Okano K, Sato K, Sugimoto M, Shimomura A, Nagao M, et al. Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. Jpn J Clin Oncol. 2022;52(8):887\u201395.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2620_CR334","doi-asserted-by":"publisher","first-page":"651","DOI":"10.18632\/oncotarget.2892","volume":"6","author":"K Shibuya","year":"2015","unstructured":"Shibuya K, Okada M, Suzuki S, Seino M, Seino S, Takeda H, et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget. 2015;6(2):651\u201361.","journal-title":"Oncotarget"},{"key":"2620_CR335","doi-asserted-by":"publisher","first-page":"176330","DOI":"10.1016\/j.ejphar.2024.176330","volume":"965","author":"X Cao","year":"2024","unstructured":"Cao X, Jiang X, Zhong ZX, Li XZ, Liu L, Li XL, et al. Drug-repurposing by virtual and experimental screening of PFKFB3 inhibitors for pancreatic cancer therapy. Eur J Pharmacol. 2024;965:176330.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2620_CR336","first-page":"1223","volume":"57","author":"D Xu","year":"2020","unstructured":"Xu D, Zhou Y, Xie X, He L, Ding J, Pang S, et al. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter\u20131 and lactate dehydrogenase A. Int J Oncol. 2020;57(5):1223\u201333.","journal-title":"Int J Oncol"},{"issue":"1","key":"2620_CR337","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-022-29684-9","volume":"13","author":"JK Nelson","year":"2022","unstructured":"Nelson JK, Thin MZ, Evan T, Howell S, Wu M, Almeida B, et al. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nat Commun. 2022;13(1):2070.","journal-title":"Nat Commun"},{"issue":"31","key":"2620_CR338","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.23.02659","volume":"42","author":"PA Philip","year":"2024","unstructured":"Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, et al. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024;42(31):3692\u2013701.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2620_CR339","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","volume":"18","author":"A Alistar","year":"2017","unstructured":"Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017;18(6):770\u20138.","journal-title":"Lancet Oncol"},{"key":"2620_CR340","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2620_CR341","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2767-9764.CRC-24-0082","volume":"4","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, et al. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARalpha, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Res Commun. 2024;4(4):1100\u201310.","journal-title":"Cancer Res Commun"},{"key":"2620_CR342","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051392","author":"J Gong","year":"2023","unstructured":"Gong J, Osipov A, Lorber J, Tighiouart M, Kwan AK, Muranaka H, et al. Combination L-glutamine with gemcitabine and Nab-paclitaxel in treatment-naive advanced pancreatic cancer: the phase I Glutapanc study protocol. Biomedicines. 2023;11(5). https:\/\/doi.org\/10.3390\/biomedicines11051392.","journal-title":"Biomedicines"},{"key":"2620_CR343","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/CEG.S390655","volume":"17","author":"R Imperial","year":"2024","unstructured":"Imperial R, Mosalem O, Majeed U, Tran NH, Borad MJ, Babiker H. Second-line treatment of pancreatic adenocarcinoma: shedding light on new opportunities and key talking points from clinical trials. Clin Exp Gastroenterol. 2024;17:121\u201334.","journal-title":"Clin Exp Gastroenterol"},{"issue":"7","key":"2620_CR344","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/MPA.0000000000000394","volume":"44","author":"JB Bachet","year":"2015","unstructured":"Bachet JB, Gay F, Marechal R, Galais MP, Adenis A, Ms CD, et al. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Pancreas. 2015;44(7):1141\u20137.","journal-title":"Pancreas"},{"key":"2620_CR345","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejca.2020.02.004","volume":"130","author":"P Hammel","year":"2020","unstructured":"Hammel P, Portales F, Mineur L, Metges JP, Andre T, De La Fouchardiere C, et al. Erratum to \u2018Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial\u2019 [European Journal of Cancer, 124 (January 2020) Pages 91\u2013101]. Eur J Cancer. 2020;130:275\u20136.","journal-title":"Eur J Cancer"},{"issue":"37","key":"2620_CR346","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1080\/14796694.2024.2395235","volume":"20","author":"CD Lopez","year":"2024","unstructured":"Lopez CD, Kardosh A, Chen EY, Pegna G, Guimaraes A, Foster B, et al. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024;20(37):2915\u201325.","journal-title":"Future Oncol"},{"issue":"17","key":"2620_CR347","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1158\/1078-0432.CCR-23-0535","volume":"29","author":"GL Beatty","year":"2023","unstructured":"Beatty GL, Delman D, Yu J, Liu M, Li JH, Zhang L, et al. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration. Clin Cancer Res. 2023;29(17):3514\u201325.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2620_CR348","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/GCO.0b013e3283409c79","volume":"23","author":"K Ino","year":"2011","unstructured":"Ino K. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol. 2011;23(1):13\u20138.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"18","key":"2620_CR349","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","volume":"25","author":"DT Le","year":"2019","unstructured":"Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, et al. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019;25(18):5493\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2620_CR350","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/oncolo\/oyac174","volume":"27","author":"JD Powderly","year":"2022","unstructured":"Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, et al. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I\/II ECHO-207\/KEYNOTE-723 Study. Oncologist. 2022;27(11):905\u2013e848.","journal-title":"Oncologist"},{"issue":"6","key":"2620_CR351","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","volume":"29","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol. 2018;29(6):1402\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"2620_CR352","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder M, Johnson M, Heist RS, Shapiro GI, Postel-Vinay S, Wilson FH, et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat Commun. 2025;16(1):423.","journal-title":"Nat Commun"},{"issue":"7","key":"2620_CR353","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/COC.0000000000000691","volume":"43","author":"PC McDonald","year":"2020","unstructured":"McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, et al. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. Am J Clin Oncol. 2020;43(7):484\u201390.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2620_CR354","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","volume":"81","author":"JF Deeken","year":"2018","unstructured":"Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, et al. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018;81(3):587\u201396.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2620_CR355","doi-asserted-by":"publisher","first-page":"e29794","DOI":"10.1371\/journal.pone.0029794","volume":"7","author":"DA Monti","year":"2012","unstructured":"Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE. 2012;7(1):e29794.","journal-title":"PLoS ONE"},{"issue":"10","key":"2620_CR356","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00432-024-05954-5","volume":"150","author":"D Witte","year":"2024","unstructured":"Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, et al. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF\/PAK-0123). J Cancer Res Clin Oncol. 2024;150(10):438.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2620_CR357","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/cts.13029","volume":"14","author":"N Fei","year":"2021","unstructured":"Fei N, Wen S, Ramanathan R, Hogg ME, Zureikat AH, Lotze MT, et al. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Clin Transl Sci. 2021;14(5):1822\u20139.","journal-title":"Clin Transl Sci"},{"issue":"21","key":"2620_CR358","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.18632\/oncotarget.27586","volume":"11","author":"KM Bever","year":"2020","unstructured":"Bever KM, Borazanci EH, Thompson EA, Durham JN, Pinero K, Jameson GS, et al. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget. 2020;11(21):1929\u201341.","journal-title":"Oncotarget"},{"issue":"5","key":"2620_CR359","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.2337\/db14-1132","volume":"64","author":"V Cifarelli","year":"2015","unstructured":"Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, et al. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. Diabetes. 2015;64(5):1632\u201342.","journal-title":"Diabetes"},{"key":"2620_CR360","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1369136","volume":"11","author":"A Linehan","year":"2024","unstructured":"Linehan A, O\u2019Reilly M, McDermott R, O\u2019Kane GM. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med Lausanne. 2024;11:1369136.","journal-title":"Front Med Lausanne"},{"key":"2620_CR361","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586959","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li W, Niu J, Fan Z, Li X, Zhang H. Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives. Front Immunol. 2025;16:1586959.","journal-title":"Front Immunol"},{"issue":"5","key":"2620_CR362","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer. Oncol Res. 2024;32(5):799\u2013805.","journal-title":"Oncol Res"},{"issue":"11","key":"2620_CR363","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.7150\/ijbs.60018","volume":"17","author":"Y Jia","year":"2021","unstructured":"Jia Y, Li HY, Wang Y, Wang J, Zhu JW, Wei YY, et al. Crosstalk between hypoxia-sensing ULK1\/2 and YAP-driven glycolysis fuels pancreatic ductal adenocarcinoma development. Int J Biol Sci. 2021;17(11):2772\u201394.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2620_CR364","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2174\/1574888X17666220827113434","volume":"18","author":"X Cao","year":"2023","unstructured":"Cao X, Cao Y, Zhao H, Wang P, Zhu Z. Prolyl 4-hydroxylase P4HA1 mediates the interplay between glucose metabolism and stemness in pancreatic cancer cells. Curr Stem Cell Res Ther. 2023;18(5):712\u20139.","journal-title":"Curr Stem Cell Res Ther"},{"key":"2620_CR365","doi-asserted-by":"publisher","first-page":"154990","DOI":"10.1016\/j.phymed.2023.154990","volume":"118","author":"Q Ruan","year":"2023","unstructured":"Ruan Q, Wen C, Jin G, Yuan Z, Yang X, Wen Z, et al. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Phytomedicine. 2023;118:154990.","journal-title":"Phytomedicine"},{"issue":"Pt 1","key":"2620_CR366","doi-asserted-by":"publisher","first-page":"125031","DOI":"10.1016\/j.talanta.2023.125031","volume":"266","author":"A Poonprasartporn","year":"2024","unstructured":"Poonprasartporn A, Xiao J, Chan KLA. A study of WZB117 as a competitive inhibitor of glucose transporter in high glucose treated PANC-1 cells by live-cell FTIR spectroscopy. Talanta. 2024;266(Pt 1):125031.","journal-title":"Talanta"},{"issue":"8","key":"2620_CR367","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","volume":"12","author":"BF Clem","year":"2013","unstructured":"Clem BF, O\u2019Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 2013;12(8):1461\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2620_CR368","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02631-6","volume":"42","author":"B Azizzadeh","year":"2025","unstructured":"Azizzadeh B, Majidinia M, Gheysarzadeh A. The reciprocal effects of autophagy and the Warburg effect in pancreatic ductal adenocarcinoma: an in vitro study. Med Oncol. 2025;42(4):86.","journal-title":"Med Oncol"},{"issue":"10","key":"2620_CR369","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/MPA.0000000000001689","volume":"49","author":"JAG Moir","year":"2020","unstructured":"Moir JAG, Long A, Haugk B, French JJ, Charnley RM, Manas DM, et al. Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer. Pancreas. 2020;49(10):1364\u201371.","journal-title":"Pancreas"},{"issue":"1","key":"2620_CR370","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12943-024-02008-9","volume":"23","author":"F Li","year":"2024","unstructured":"Li F, Si W, Xia L, Yin D, Wei T, Tao M, et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer. 2024;23(1):90.","journal-title":"Mol Cancer"},{"issue":"10","key":"2620_CR371","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nchembio.2143","volume":"12","author":"A Boudreau","year":"2016","unstructured":"Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016;12(10):779\u201386.","journal-title":"Nat Chem Biol"},{"key":"2620_CR372","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-020-0210-2","volume":"8","author":"DA Richardson","year":"2020","unstructured":"Richardson DA, Sritangos P, James AD, Sultan A, Bruce JIE. Metabolic regulation of calcium pumps in pancreatic cancer: role of phosphofructokinase-fructose-bisphosphatase-3 (PFKFB3). Cancer Metab. 2020;8:2.","journal-title":"Cancer Metab"},{"issue":"1","key":"2620_CR373","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01334-z","volume":"9","author":"M Geyer","year":"2023","unstructured":"Geyer M, Schreyer D, Gaul LM, Pfeffer S, Pilarsky C, Queiroz K. A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discov. 2023;9(1):20.","journal-title":"Cell Death Discov"},{"issue":"12","key":"2620_CR374","first-page":"5507","volume":"9","author":"C Chen","year":"2017","unstructured":"Chen C, Xiao W, Huang L, Yu G, Ni J, Yang L, et al. Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1\/RIP3 and synergizes the activity of gemcitabine. Am J Transl Res. 2017;9(12):5507\u201317.","journal-title":"Am J Transl Res"},{"issue":"1","key":"2620_CR375","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","volume":"5","author":"J Encarnacion-Rosado","year":"2024","unstructured":"Encarnacion-Rosado J, Sohn ASW, Biancur DE, Lin EY, Osorio-Vasquez V, Rodrick T, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat Cancer. 2024;5(1):85\u201399.","journal-title":"Nat Cancer"},{"key":"2620_CR376","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12101818","author":"N Ammar","year":"2023","unstructured":"Ammar N, Hildebrandt M, Geismann C, Roder C, Gemoll T, Sebens S, et al. Monocarboxylate transporter-1 (MCT1)-mediated lactate uptake protects pancreatic adenocarcinoma cells from oxidative stress during glutamine scarcity thereby promoting resistance against inhibitors of glutamine metabolism. Antioxidants. 2023;12(10). https:\/\/doi.org\/10.3390\/antiox12101818.","journal-title":"Antioxidants"},{"issue":"2","key":"2620_CR377","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gutjnl-2021-325117","volume":"72","author":"MC De Santis","year":"2023","unstructured":"De Santis MC, Gozzelino L, Margaria JP, Costamagna A, Ratto E, Gulluni F, et al. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut. 2023;72(2):360\u201371.","journal-title":"Gut"},{"issue":"36","key":"2620_CR378","doi-asserted-by":"publisher","first-page":"E5328","DOI":"10.1073\/pnas.1611406113","volume":"113","author":"A Elgogary","year":"2016","unstructured":"Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, et al. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016;113(36):E5328\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2620_CR379","doi-asserted-by":"publisher","first-page":"e2412032","DOI":"10.4014\/jmb.2412.12032","volume":"35","author":"DH Kim","year":"2025","unstructured":"Kim DH, Kim DJ, Park SJ, Jang WJ, Jeong CH. Inhibition of GLS1 and ASCT2 synergistically enhances the anticancer effects in pancreatic cancer cells. J Microbiol Biotechnol. 2025;35:e2412032.","journal-title":"J Microbiol Biotechnol"},{"key":"2620_CR380","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.trsl.2022.11.007","volume":"255","author":"Z Tian","year":"2023","unstructured":"Tian Z, Tan Y, Lin X, Su M, Pan L, Lin L, et al. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1\/PI3K\/AKT\/mTOR axis. Transl Res. 2023;255:66\u201376.","journal-title":"Transl Res"},{"key":"2620_CR381","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3389\/fphys.2018.00833","volume":"9","author":"H Tanton","year":"2018","unstructured":"Tanton H, Voronina S, Evans A, Armstrong J, Sutton R, Criddle DN, et al. F(1)F(0)-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. Front Physiol. 2018;9:833.","journal-title":"Front Physiol"},{"issue":"9","key":"2620_CR382","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.isci.2024.110642","volume":"27","author":"J Choi","year":"2024","unstructured":"Choi J, Smith DM, Lee YJ, Cai D, Hossain MJ, O\u2019Connor TJ, et al. Etomoxir repurposed as a promiscuous fatty acid mimetic chemoproteomic probe. iScience. 2024;27(9):110642.","journal-title":"iScience"},{"key":"2620_CR383","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189698","author":"S Durasevic","year":"2021","unstructured":"Durasevic S, Ruzicic A, Lakic I, Tosti T, Durovic S, Glumac S, et al. The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats. Int J Mol Sci. 2021;22(18). https:\/\/doi.org\/10.3390\/ijms22189698.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2620_CR384","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.canlet.2011.05.002","volume":"308","author":"PA Phillips","year":"2011","unstructured":"Phillips PA, Sangwan V, Borja-Cacho D, Dudeja V, Vickers SM, Saluja AK. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett. 2011;308(2):181\u20138.","journal-title":"Cancer Lett"},{"key":"2620_CR385","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1476-4598-5-76","volume":"5","author":"MB Ujiki","year":"2006","unstructured":"Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ, Golkar L, Milam B, et al. Apigenin inhibits pancreatic cancer cell proliferation through G2\/M cell cycle arrest. Mol Cancer. 2006;5:76.","journal-title":"Mol Cancer"},{"key":"2620_CR386","doi-asserted-by":"publisher","unstructured":"Sandforth L, Ammar N, Dinges LA, Rocken C, Arlt A, Sebens S, et al. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells dagger. Cancers (Basel). 2020;12(3). https:\/\/doi.org\/10.3390\/cancers12030581.","DOI":"10.3390\/cancers12030581"},{"issue":"7","key":"2620_CR387","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1038\/oncsis.2017.54","volume":"6","author":"AJ Rice","year":"2017","unstructured":"Rice AJ, Cortes E, Lachowski D, Cheung BCH, Karim SA, Morton JP, et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017;6(7):e352.","journal-title":"Oncogenesis"},{"issue":"18","key":"2620_CR388","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1158\/0008-5472.CAN-23-1895","volume":"84","author":"M Zarei","year":"2024","unstructured":"Zarei M, Hajihassani O, Hue JJ, Loftus AW, Graor HJ, Nakazzi F, et al. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Res. 2024;84(18):3072\u201385.","journal-title":"Cancer Res"},{"issue":"1","key":"2620_CR389","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41420-024-01862-2","volume":"10","author":"Q Meng","year":"2024","unstructured":"Meng Q, Xie Y, Sun K, He L, Wu H, Zhang Q, et al. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Cell Death Discov. 2024;10(1):97.","journal-title":"Cell Death Discov"},{"issue":"30","key":"2620_CR390","doi-asserted-by":"publisher","first-page":"48660","DOI":"10.18632\/oncotarget.12650","volume":"8","author":"E Petrova","year":"2017","unstructured":"Petrova E, Scholz A, Paul J, Sturz A, Haike K, Siegel F, et al. Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth. Oncotarget. 2017;8(30):48660\u201370.","journal-title":"Oncotarget"},{"issue":"1","key":"2620_CR391","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13046-024-03072-1","volume":"43","author":"E Ibello","year":"2024","unstructured":"Ibello E, Saracino F, Delle Cave D, Buonaiuto S, Amoroso F, Andolfi G, et al. Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism. J Exp Clin Cancer Res. 2024;43(1):165.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2620_CR392","doi-asserted-by":"publisher","first-page":"108231","DOI":"10.1016\/j.celrep.2020.108231","volume":"33","author":"KER Hollinshead","year":"2020","unstructured":"Hollinshead KER, Parker SJ, Eapen VV, Encarnacion-Rosado J, Sohn A, Oncu T, et al. Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. Cell Rep. 2020;33(1):108231.","journal-title":"Cell Rep"},{"key":"2620_CR393","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2020.104788","volume":"65","author":"K Pandey","year":"2020","unstructured":"Pandey K, Tripathi SK, Panda M, Biswal BK. Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway. Toxicol In Vitro. 2020;65:104788.","journal-title":"Toxicol In Vitro"},{"issue":"7","key":"2620_CR394","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.13583","volume":"18","author":"M Pujalte-Martin","year":"2024","unstructured":"Pujalte-Martin M, Belaid A, Bost S, Kahi M, Peraldi P, Rouleau M, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024;18(7):1719\u201338.","journal-title":"Mol Oncol"},{"key":"2620_CR395","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2019.08.002","volume":"465","author":"EA Choi","year":"2019","unstructured":"Choi EA, Choi YS, Lee EJ, Singh SR, Kim SC, Chang S. A pharmacogenomic analysis using L1000CDS(2) identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Cancer Lett. 2019;465:82\u201393.","journal-title":"Cancer Lett"},{"key":"2620_CR396","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2020;11:621093.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2620_CR397","doi-asserted-by":"publisher","first-page":"106899","DOI":"10.1016\/j.isci.2023.106899","volume":"26","author":"G Reyes-Castellanos","year":"2023","unstructured":"Reyes-Castellanos G, Abdel Hadi N, Gallardo-Arriaga S, Masoud R, Garcia J, Lac S, et al. Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo. iScience. 2023;26(6):106899.","journal-title":"iScience"},{"issue":"12","key":"2620_CR398","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acsmedchemlett.2c00404","volume":"13","author":"RD Gao","year":"2022","unstructured":"Gao RD, Maeda M, Tallon C, Feinberg AP, Slusher BS, Tsukamoto T. Effects of 6-aminonicotinic acid esters on the reprogrammed epigenetic state of distant metastatic pancreatic carcinoma. ACS Med Chem Lett. 2022;13(12):1892\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"2620_CR399","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1074\/jbc.RA119.012186","volume":"295","author":"X Song","year":"2020","unstructured":"Song X, Akasaka H, Wang H, Abbasgholizadeh R, Shin JH, Zang F, et al. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. J Biol Chem. 2020;295(8):2348\u201358.","journal-title":"J Biol Chem"},{"issue":"2","key":"2620_CR400","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/17501911.2024.2441652","volume":"17","author":"R Akhlaq","year":"2025","unstructured":"Akhlaq R, Ahmed T, Khan T, Yaseen Jeelani SU, Joseph-Chowdhury JN, Sidoli S, et al. PX-12 modulates vorinostat-induced acetylation and methylation marks in CAL 27 cells. Epigenomics. 2025;17(2):79\u201387.","journal-title":"Epigenomics"},{"issue":"1","key":"2620_CR401","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13046-022-02270-z","volume":"41","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xu HX, Cho WCS, Cheuk W, Li Y, Huang QH, et al. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. J Exp Clin Cancer Res. 2022;41(1):90.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2620_CR402","doi-asserted-by":"publisher","first-page":"200","DOI":"10.37349\/etat.2020.00013","volume":"1","author":"ZW Sin","year":"2020","unstructured":"Sin ZW, Bhardwaj V, Pandey AK, Garg M. A brief overview of antitumoral actions of bruceine D. Explor Target Antitumor Ther. 2020;1(4):200\u201317.","journal-title":"Explor Target Antitumor Ther"},{"key":"2620_CR403","doi-asserted-by":"publisher","first-page":"1146115","DOI":"10.3389\/fmed.2023.1146115","volume":"10","author":"M Mijit","year":"2023","unstructured":"Mijit M, Boner M, Cordova RA, Gampala S, Kpenu E, Klunk AJ, et al. Activation of the integrated stress response (ISR) pathways in response to Ref-1 inhibition in human pancreatic cancer and its tumor microenvironment. Front Med (Lausanne). 2023;10:1146115.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"2620_CR404","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","volume":"40","author":"DD Shi","year":"2022","unstructured":"Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, et al. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022;40(9):939\u201356. e16.","journal-title":"Cancer Cell"},{"issue":"1","key":"2620_CR405","doi-asserted-by":"publisher","first-page":"153","DOI":"10.21873\/anticanres.13936","volume":"40","author":"EHU Wendt","year":"2020","unstructured":"Wendt EHU, Schoenrogge M, Vollmar B, Zechner D. Galloflavin plus metformin treatment impairs pancreatic cancer cells. Anticancer Res. 2020;40(1):153\u201360.","journal-title":"Anticancer Res"},{"issue":"15","key":"2620_CR406","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/0008-5472.CAN-10-2016","volume":"71","author":"Y Gao","year":"2011","unstructured":"Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 2011;71(15):5182\u201393.","journal-title":"Cancer Res"},{"issue":"3","key":"2620_CR407","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214294","volume":"14","author":"L Mouhid","year":"2019","unstructured":"Mouhid L, de Gomez Cedron M, Garcia-Carrascosa E, Reglero G, Fornari T, de Ramirez Molina A. Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer. PLoS One. 2019;14(3):e0214294.","journal-title":"PLoS One"},{"issue":"11","key":"2620_CR408","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1021\/acschembio.0c00546","volume":"15","author":"H Karaboga","year":"2020","unstructured":"Karaboga H, Huang W, Srivastava S, Widmann S, Addanki S, Gamage KT, et al. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity. ACS Chem Biol. 2020;15(11):2916\u201328.","journal-title":"ACS Chem Biol"},{"issue":"3","key":"2620_CR409","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1142\/S0192415X23500362","volume":"51","author":"L Hu","year":"2023","unstructured":"Hu L, Xu X, Chen X, Qiu S, Li Q, Zhang D, et al. Epigallocatechin-3-Gallate Decreases Hypoxia-Inducible Factor-1 in Pancreatic Cancer Cells. Am J Chin Med. 2023;51(3):761\u201377.","journal-title":"Am J Chin Med"},{"issue":"3","key":"2620_CR410","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14740338.2020.1715939","volume":"19","author":"N Alkhushaym","year":"2020","unstructured":"Alkhushaym N, Almutairi AR, Althagafi A, Fallatah SB, Oh M, Martin JR, et al. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert Opin Drug Saf. 2020;19(3):327\u201334.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2620_CR411","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1248\/bpb.b19-00435","volume":"43","author":"T Kawashiri","year":"2020","unstructured":"Kawashiri T, Tokunaga A, Kobayashi D, Shimazoe T. Anti-tumor activities of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and bisphosphonates in pancreatic cell lines which show poor responses to gemcitabine. Biol Pharm Bull. 2020;43(1):49\u201352.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"2620_CR412","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.dld.2020.01.008","volume":"52","author":"D Tamburrino","year":"2020","unstructured":"Tamburrino D, Crippa S, Partelli S, Archibugi L, Arcidiacono PG, Falconi M, et al. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig Liver Dis. 2020;52(4):392\u20139.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"2620_CR413","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1097\/MPA.0000000000001276","volume":"48","author":"D Wang","year":"2019","unstructured":"Wang D, Rodriguez EA, Barkin JS, Donath EM, Pakravan AS. Statin use shows increased overall survival in patients diagnosed with pancreatic cancer: a meta-analysis. Pancreas. 2019;48(4):e22-3.","journal-title":"Pancreas"},{"issue":"2","key":"2620_CR414","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MPA.0000000000001737","volume":"50","author":"K Skrypek","year":"2021","unstructured":"Skrypek K, Balog S, Eriguchi Y, Asahina K. Inhibition of stearoyl-CoA desaturase induces the unfolded protein response in pancreatic tumors and suppresses their growth. Pancreas. 2021;50(2):219\u201326.","journal-title":"Pancreas"},{"key":"2620_CR415","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.02.018","author":"SC Shin","year":"2020","unstructured":"Shin SC, Thomas D, Radhakrishnan P, Hollingsworth MA. Invasive phenotype induced by low extracellular pH requires mitochondria dependent metabolic flexibility. Biochem Biophys Res Commun. 2020. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.018.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2620_CR416","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.18632\/aging.103033","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Yu T, Zhou Y, Wang S, Zhou X, Wang L, et al. Carnitine palmitoyltransferase 1\u00a0C contributes to progressive cellular senescence. Aging. 2020;12(8):6733\u201355.","journal-title":"Aging"},{"issue":"3","key":"2620_CR417","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1021\/nn504025a","volume":"9","author":"SS Lee","year":"2015","unstructured":"Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano. 2015;9(3):2420\u201332.","journal-title":"ACS Nano"},{"issue":"1","key":"2620_CR418","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12967-024-05598-6","volume":"22","author":"M Mascaraque","year":"2024","unstructured":"Mascaraque M, Courtois S, Royo-Garcia A, Barneda D, Stoian AM, Villaoslada I, et al. Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells. J Transl Med. 2024;22(1):797.","journal-title":"J Transl Med"},{"issue":"9","key":"2620_CR419","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-17-1148","volume":"17","author":"KM Lemberg","year":"2018","unstructured":"Lemberg KM, Vornov JJ, Rais R, Slusher BS. We\u2019re not DON yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17(9):1824\u201332.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2620_CR420","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3724\/abbs.2023029","volume":"55","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Deng S, Liu H, Wang R, Liu Y, Dai Z, et al. Glutamine deprivation induces ferroptosis in pancreatic cancer cells. Acta Biochim Biophys Sin (Shanghai). 2023;55(8):1288\u2013300.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"2620_CR421","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI127515","volume":"130","author":"NS Sharma","year":"2020","unstructured":"Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020;130(1):451\u201365.","journal-title":"J Clin Invest"},{"key":"2620_CR422","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1921609","volume":"2020","author":"C Jia","year":"2020","unstructured":"Jia C, Li H, Fu D, Lan Y. GFAT1\/HBP\/O-GlcNAcylation axis regulates beta-catenin activity to promote pancreatic cancer aggressiveness. Biomed Res Int. 2020;2020:1921609.","journal-title":"Biomed Res Int"},{"issue":"11","key":"2620_CR423","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc.2016.114","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(11):749.","journal-title":"Nat Rev Cancer"},{"key":"2620_CR424","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003014118","author":"PY Tsai","year":"2021","unstructured":"Tsai PY, Lee MS, Jadhav U, Naqvi I, Madha S, Adler A, et al. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Proc Natl Acad Sci U S A. 2021;118(10). https:\/\/doi.org\/10.1073\/pnas.2003014118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2620_CR425","doi-asserted-by":"publisher","first-page":"15965","DOI":"10.1038\/ncomms15965","volume":"8","author":"DE Biancur","year":"2017","unstructured":"Biancur DE, Paulo JA, Malachowska B, Quiles Del Rey M, Sousa CM, Wang X, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017;8:15965.","journal-title":"Nat Commun"},{"issue":"12","key":"2620_CR426","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s42255-020-00315-1","volume":"2","author":"S Raho","year":"2020","unstructured":"Raho S, Capobianco L, Malivindi R, Vozza A, Piazzolla C, De Leonardis F, et al. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth. Nat Metab. 2020;2(12):1373\u201381.","journal-title":"Nat Metab"},{"key":"2620_CR427","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.963066","volume":"13","author":"G Gauthier-Coles","year":"2022","unstructured":"Gauthier-Coles G, Broer A, McLeod MD, George AJ, Hannan RD, Broer S. Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells. Front Pharmacol. 2022;13:963066.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2620_CR428","doi-asserted-by":"publisher","first-page":"e23192","DOI":"10.1002\/jbt.23192","volume":"36","author":"PDP Akuetteh","year":"2022","unstructured":"Akuetteh PDP, Huang H, Wu S, Zhou H, Jin G, Hong W, et al. Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. J Biochem Mol Toxicol. 2022;36(11):e23192.","journal-title":"J Biochem Mol Toxicol"},{"key":"2620_CR429","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051113","author":"H Jo","year":"2022","unstructured":"Jo H, Lee D, Go C, Jang Y, Bae S, Agura T, et al. Alloferon affects the chemosensitivity of pancreatic cancer by regulating the expression of SLC6A14. Biomedicines. 2022;10(5). https:\/\/doi.org\/10.3390\/biomedicines10051113.","journal-title":"Biomedicines"},{"issue":"8","key":"2620_CR430","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/ijc.23723","volume":"123","author":"TL Bowles","year":"2008","unstructured":"Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer. 2008;123(8):1950\u20135.","journal-title":"Int J Cancer"},{"issue":"2","key":"2620_CR431","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7150\/thno.40195","volume":"10","author":"SS Kim","year":"2020","unstructured":"Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 2020;10(2):829\u201340.","journal-title":"Theranostics"},{"issue":"1","key":"2620_CR432","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0102-9","volume":"33","author":"R Daylami","year":"2014","unstructured":"Daylami R, Muilenburg DJ, Virudachalam S, Bold RJ. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res. 2014;33(1):102.","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"2620_CR433","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1158\/1078-0432.CCR-19-0206","volume":"25","author":"BC Prudner","year":"2019","unstructured":"Prudner BC, Rathore R, Robinson AM, Godec A, Chang SF, Hawkins WG, et al. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Clin Cancer Res. 2019;25(16):5122\u201334.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2620_CR434","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1535-7163.MCT-18-0708","volume":"18","author":"PK Singh","year":"2019","unstructured":"Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, et al. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation. Mol Cancer Ther. 2019;18(12):2381\u201393.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"2620_CR435","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1002\/cncr.30897","volume":"123","author":"MA Lowery","year":"2017","unstructured":"Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, et al. <article-title update=\"added\">A phase 1\/1B trial of ADI\u2010PEG 20 plus nab\u2010paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 2017;123(23):4556\u201365.","journal-title":"Cancer"},{"issue":"2","key":"2620_CR436","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","volume":"3","author":"I Theate","year":"2015","unstructured":"Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015;3(2):161\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2620_CR437","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4103\/0366-6999.201613","volume":"130","author":"T Zhang","year":"2017","unstructured":"Zhang T, Tan XL, Xu Y, Wang ZZ, Xiao CH, Liu R. Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer. Chin Med J (Engl). 2017;130(6):710\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"2620_CR438","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2326-6066.CIR-14-0214","volume":"3","author":"ER Manuel","year":"2015","unstructured":"Manuel ER, Chen J, D\u2019Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, et al. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res. 2015;3(9):1096\u2013107.","journal-title":"Cancer Immunol Res"},{"issue":"24","key":"2620_CR439","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77(24):6795\u2013811.","journal-title":"Cancer Res"},{"issue":"1","key":"2620_CR440","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000249","volume":"3","author":"A Naing","year":"2024","unstructured":"Naing A, Papadopoulos KP, Pishvaian MJ, Rahma O, Hanna GJ, Garralda E, et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. 2024;3(1):e000249.","journal-title":"BMJ Oncol"},{"issue":"1","key":"2620_CR441","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.13871","volume":"174","author":"D Aden","year":"2025","unstructured":"Aden D, Sureka N, Zaheer S, Chaurasia JK, Zaheer S. Metabolic reprogramming in cancer: implications for immunosuppressive microenvironment. Immunology. 2025;174(1):30\u201372.","journal-title":"Immunology"},{"issue":"12","key":"2620_CR442","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1038\/s12276-025-01590-2","volume":"57","author":"H Jeong","year":"2025","unstructured":"Jeong H, Lee J, Son JY, Lee J, Kang M, Cho S, et al. ULK1 knockout suppresses pancreatic cancer progression by inhibiting autophagy and enhancing antitumor immunity. Exp Mol Med. 2025;57(12):2816\u201332.","journal-title":"Exp Mol Med"},{"issue":"48","key":"2620_CR443","doi-asserted-by":"publisher","first-page":"28726","DOI":"10.1074\/jbc.A114.627778","volume":"290","author":"KJ Petherick","year":"2015","unstructured":"Petherick KJ, Conway OJ, Mpamhanga C, Osborne SA, Kamal A, Saxty B, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015;290(48):28726.","journal-title":"J Biol Chem"},{"issue":"5","key":"2620_CR444","first-page":"1384","volume":"10","author":"B Singha","year":"2020","unstructured":"Singha B, Laski J, Ramos Valdes Y, Liu E, DiMattia GE, Shepherd TG. Inhibiting ULK1 kinase decreases autophagy and cell viability in high-grade serous ovarian cancer spheroids. Am J Cancer Res. 2020;10(5):1384\u201399.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2620_CR445","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.molcel.2015.05.031","volume":"59","author":"DF Egan","year":"2015","unstructured":"Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol Cell. 2015;59(2):285\u201397.","journal-title":"Mol Cell"},{"issue":"6","key":"2620_CR446","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.3892\/or.2017.5635","volume":"37","author":"F Tang","year":"2017","unstructured":"Tang F, Hu P, Yang Z, Xue C, Gong J, Sun S, et al. SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways. Oncol Rep. 2017;37(6):3449\u201358.","journal-title":"Oncol Rep"},{"key":"2620_CR447","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2119\/molmed.2016.00034","volume":"22","author":"J Xiao","year":"2016","unstructured":"Xiao J, Feng X, Huang XY, Huang Z, Huang Y, Li C, et al. Spautin-1 Ameliorates Acute Pancreatitis via Inhibiting Impaired Autophagy and Alleviating Calcium Overload. Mol Med. 2016;22:643\u201352.","journal-title":"Mol Med"},{"issue":"12","key":"2620_CR448","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/nchembio.1681","volume":"10","author":"B Ronan","year":"2014","unstructured":"Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014;10(12):1013\u20139.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2620_CR449","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1634\/theoncologist.2014-0086","volume":"19","author":"BM Wolpin","year":"2014","unstructured":"Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19(6):637\u20138.","journal-title":"Oncologist"},{"issue":"18","key":"2620_CR450","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.7150\/thno.60437","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Tao Y, He M, Deng M, Guo R, Sheng Q, et al. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Theranostics. 2021;11(18):8692\u2013705.","journal-title":"Theranostics"},{"issue":"13","key":"2620_CR451","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1245\/s10434-015-4566-4","volume":"22","author":"BA Boone","year":"2015","unstructured":"Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, et al. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22(13):4402\u201310.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2620_CR452","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00280-017-3446-y","volume":"80","author":"P Samaras","year":"2017","unstructured":"Samaras P, Tusup M, Nguyen-Kim TDL, Seifert B, Bachmann H, von Moos R, et al. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2017;80(5):1005\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2620_CR453","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","volume":"5","author":"TB Karasic","year":"2019","unstructured":"Karasic TB, O\u2019Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, et al. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(7):993\u20138.","journal-title":"JAMA Oncol"},{"key":"2620_CR454","doi-asserted-by":"publisher","first-page":"751568","DOI":"10.3389\/fphar.2021.751568","volume":"12","author":"AG Raufi","year":"2021","unstructured":"Raufi AG, Liguori NR, Carlsen L, Parker C, Hernandez Borrero L, Zhang S, et al. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Front Pharmacol. 2021;12:751568.","journal-title":"Front Pharmacol"},{"issue":"9","key":"2620_CR455","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1535-7163.MCT-20-0962","volume":"20","author":"I Ferrarini","year":"2021","unstructured":"Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a novel mitocan acting synergistically with glycolysis inhibition in pancreatic cancer. Mol Cancer Ther. 2021;20(9):1572\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"7806","key":"2620_CR456","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100\u20135.","journal-title":"Nature"},{"issue":"5","key":"2620_CR457","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41580-019-0120-8","volume":"20","author":"KL Bryant","year":"2019","unstructured":"Bryant KL, Der CJ. Blocking autophagy to starve pancreatic cancer. Nat Rev Mol Cell Biol. 2019;20(5):265.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2620_CR458","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3324\/haematol.2023.283224","volume":"109","author":"JA Schmid","year":"2024","unstructured":"Schmid JA, Festl Y, Severin Y, Bacher U, Kronig MN, Snijder B, et al. Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options. Haematologica. 2024;109(2):617\u201321.","journal-title":"Haematologica"},{"issue":"4","key":"2620_CR459","first-page":"1253","volume":"109","author":"RA Pan","year":"2024","unstructured":"Pan RA, Wang Y, Qiu S, Villalobos-Ortiz M, Ryan J, Morris E, et al. BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics. Haematologica. 2024;109(4):1253\u20138.","journal-title":"Haematologica"},{"issue":"1","key":"2620_CR460","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1038\/s41467-025-61242-x","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Santana-Codina N, Yu Q, Poupault C, Campos C, Qin X, et al. De novo pyrimidine biosynthesis inhibition synergizes with BCL-X(L) targeting in pancreatic cancer. Nat Commun. 2025;16(1):6987.","journal-title":"Nat Commun"},{"key":"2620_CR461","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123113","volume":"357","author":"P Huang","year":"2024","unstructured":"Huang P, Wolde T, Bhardwaj V, Zhang X, Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy. Life Sci. 2024;357:123113.","journal-title":"Life Sci"},{"issue":"11","key":"2620_CR462","doi-asserted-by":"publisher","first-page":"e0294065","DOI":"10.1371\/journal.pone.0294065","volume":"18","author":"K Ingle","year":"2023","unstructured":"Ingle K, LaComb JF, Graves LM, Baines AT, Bialkowska AB. AUM302, a novel triple kinase PIM\/PI3K\/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLoS One. 2023;18(11):e0294065.","journal-title":"PLoS One"},{"issue":"1","key":"2620_CR463","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04504-6","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lin Z, Lin Q, Bei W, Guo J. Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. Cell Death Dis. 2022;13(1):62.","journal-title":"Cell Death Dis"},{"key":"2620_CR464","doi-asserted-by":"publisher","unstructured":"Zhang X, Pandey V, Bhardwaj V, Zhu T, Lobie PE. Autocrine\/paracrine growth hormone in cancer progression. Endocr Relat Cancer. 2024;31(1). https:\/\/doi.org\/10.1530\/ERC-23-0120.","DOI":"10.1530\/ERC-23-0120"},{"issue":"11","key":"2620_CR465","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41389-019-0173-8","volume":"8","author":"M Zhang","year":"2019","unstructured":"Zhang M, Wang B, Chong QY, Pandey V, Guo Z, Chen RM, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1\/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8(11):65.","journal-title":"Oncogenesis"},{"issue":"8","key":"2620_CR466","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tem.2017.05.003","volume":"28","author":"JK Perry","year":"2017","unstructured":"Perry JK, Wu ZS, Mertani HC, Zhu T, Lobie PE. Tumour-derived human growth hormone as a therapeutic target in oncology. Trends Endocrinol Metab. 2017;28(8):587\u201396.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2620_CR467","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s13402-021-00614-z","volume":"44","author":"R Shimazaki","year":"2021","unstructured":"Shimazaki R, Takano S, Satoh M, Takada M, Miyahara Y, Sasaki K, et al. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol (Dordr). 2021;44(4):937\u201350.","journal-title":"Cell Oncol (Dordr)"},{"key":"2620_CR468","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-385233-5.00002-7","volume":"97","author":"AD Rhim","year":"2010","unstructured":"Rhim AD, Stanger BZ. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Prog Mol Biol Transl Sci. 2010;97:41\u201378.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"2620_CR469","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1021\/acsptsci.2c00044","volume":"5","author":"V Pandey","year":"2022","unstructured":"Pandey V, Zhang X, Poh HM, Wang B, Dukanya D, Ma L, et al. Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival. ACS Pharmacol Transl Sci. 2022;5(9):761\u201373.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"2620_CR470","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41419-022-04700-4","volume":"13","author":"F Cheng","year":"2022","unstructured":"Cheng F, Wang X, Chiou YS, He C, Guo H, Tan YQ, et al. Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death Dis. 2022;13(3):265.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2620_CR471","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41388-024-03244-5","volume":"44","author":"S Zhang","year":"2025","unstructured":"Zhang S, Tan YQ, Zhang X, Basappa B, Zhu T, Pandey V, et al. TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma. Oncogene. 2025;44(11):753\u201368.","journal-title":"Oncogene"},{"key":"2620_CR472","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211014818","volume":"14","author":"J Chi","year":"2021","unstructured":"Chi J, Chung SY, Parakrama R, Fayyaz F, Jose J, Saif MW. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Therap Adv Gastroenterol. 2021;14:17562848211014818.","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"2620_CR473","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tips.2020.11.009","volume":"42","author":"C Ma","year":"2021","unstructured":"Ma C, Peng Y, Li H, Chen W. Organ-on-a-Chip: a new paradigm for drug development. Trends Pharmacol Sci. 2021;42(2):119\u201333.","journal-title":"Trends Pharmacol Sci"},{"key":"2620_CR474","doi-asserted-by":"publisher","unstructured":"Wolde T, Bhardwaj V, Pandey V. Current Bioinformatics Tools in Precision Oncology. MedComm (2020). 2025;6(7):e70243. https:\/\/doi.org\/10.1002\/mco2.70243.","DOI":"10.1002\/mco2.70243"},{"key":"2620_CR475","doi-asserted-by":"publisher","first-page":"852746","DOI":"10.3389\/fonc.2022.852746","volume":"12","author":"V Bhardwaj","year":"2022","unstructured":"Bhardwaj V, Sharma A, Parambath SV, Gul I, Zhang X, Lobie PE, et al. Machine Learning for Endometrial Cancer Prediction and Prognostication. Front Oncol. 2022;12:852746.","journal-title":"Front Oncol"},{"issue":"10","key":"2620_CR476","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/medethics-2021-107529","volume":"48","author":"JJ Wadden","year":"2022","unstructured":"Wadden JJ. Defining the undefinable: the black box problem in healthcare artificial intelligence. J Med Ethics. 2022;48(10):764.","journal-title":"J Med Ethics"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02620-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:02:47Z","timestamp":1776304967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02620-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":476,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02620-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}